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 ABSTRACT OF THE DISSERTATION
 STRUCTURE AND MECHANISM OF MYCOBACTERIAL TOPOISOMERASE I
 by
 Nan Cao
 Florida International University, 2018
 Miami, Florida
 Professor Yuk-Ching Tse-Dinh, Major Professor
 The enzyme DNA topoisomerase I is an essential enzyme that plays an 
important role in eukaryotic and prokaryotic cellular processes such as DNA 
replication, transcription, recombination and repair. Mycobacterium tuberculosis 
topoisomerase I (MtTOP1) is a validated drug target for antituberculosis 
treatment. Mycobacterial topoisomerase I regulates the topological constraints in 
chromosomes and helps in maintaining the growth of mycobacteria. The N- 
terminal domain (NTD) of mycobacterial topoisomerase I contains conserved 
catalytic domains that along with the active site Tyrosine are involved in cleaving 
and rejoining a single strand of DNA. Magnesium is required in DNA cleavage 
activity of type IA topoisomerases. The C-terminal domain (CTD) of 
mycobacterial topoisomerase I is divided into four subdomains (D5-D8) and a 
positively charged tail. Each subdomain has a GxxGPY sequence motif. The 
DNA binding, relaxation, cleavage, religation, catenation and decatenation ability 
of each subdomains of CTD were studied. The present study shows that each
	 vii	
subdomain has its own characteristics.  Subdomain D8 and D7 are responsible 
for maintaining the relaxation activity of mycobacterial topoisomerase I.  
Subdomain D5 is essential to maintain the DNA cleavage, religation, catenation 
and decatenation activity.  A new crystal structure of MtTOP1-704t (amino acids 
A2-T704 containing NTD+D5 domains) was obtained.  Structures with ssDNA 
substrate bound to the active site (Y342) in the presence and absence of Mg2+ 
were also investigated.  Significant enzyme conformational changes upon DNA 
binding place the catalytic tyrosine in a pre-transition position for cleavage of a 
specific phosphodiester linkage to form a covalent intermediate. Meanwhile, the 
enzyme/DNA complex with Mg2+ bound at active site may present the post-
transition state for religation in the enzyme’s multiple-state DNA relaxation 
activity. The critical function of a strictly conserved glutamic acid in acid-base 
catalysis of the DNA cleavage step was also demonstrated by site-directed 
mutagenesis. The present work provides new functional insights into the more 
stringent requirement for DNA rejoining versus cleavage by type IA 
topoisomerase, and further establishes the potential for select interference of 
DNA rejoining via specific inhibitors.   
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INTRODUCTION 
I.1 Tuberculosis 
Tuberculosis (TB) is a fatal airborne disease.  It is a global health problem 
and kills millions of people annually.  In 2016, 6.3 million new TB cases were 
reported, and 1.3 million people died from TB worldwide.  The World Health 
Organization (WHO) estimates that 10.4 million people are currently infected by 
TB. Most of the new cases are in low-income countries in Asia and African.  As 
TB is one of the top causes of human mortality (Fogel, 2015), much effort has 
been devoted to diagnosis, prevention and treatment TB. The world health 
organization’s end TB strategy plans to stop TB in 2030~2035 (WHO, 2017).  
Mycobacterium tuberculosis (M. tuberculosis) is a pathogenic bacterium 
and is the cause of TB (Tang et al., 2016).  The genome of Mycobacterium 
tuberculosis H37RV was sequenced, and pathogenic factors were characterized 
(Glickman and Jr., 2001).  Mycobacterium tuberculosis is mainly transmitted in 
the aerosol droplet and passes through the upper respiratory tract. 
Mycobacterium tuberculosis infects lungs, but the infection also involves other 
organs (Piccini et al., 2014).  Mycobacterium tuberculosis has the characteristics 
of both Gram-negative and Gram-positive bacteria (Fu and Fu-Liu, 2002). The 
cell wall of Mycobacterium tuberculosis is distinctive and impermeable. It is 
difficult to characterize between Gram-negative and Gram-positive cell wall.  The 
thick outer layer membrane contains mycolic acid and outermost capsule 
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composed of polysaccharides (Jankute et al., 2015).  The three basic structure 
component of Mycobacterium tuberculosis cell wall are, long-chain mycolic acids, 
highly branched arabinogalactan based polysaccharide, and cross-linked 
network of peptidoglycan (Figure I.1) (Bhat et al., 2017; Jankute et al., 2015; 
Smith, 2017).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
duces cell membrane energy, disrupting the
proton motive force and affecting membrane
transport [14]. EMB is a bacteriostatic agent
that inhibits the polymerization of arabinan,
arabinogalactan, and lipoarabinomannan,
thus preventing its biogenesis formation on
the cell wall [15]. Drug resistance in M. tu-
berculosis is due to spontaneous chromoso-
mal mutations and is worsened by the
absence or inefficiency of resistance-medi-
ating genetic elements such as transposons
and plasmids [16,17].
Drug resistance in TB is a direct off-
spring of incomplete or inadequate drug
treatment regimens; inadequate treatment of
TB regimens often only acts on drug-sus-
ceptible strains, allowing drug-resistant
species to survive and amplify. Multi drug-
resistant TB (MDR-TB) is defined as active
tuberculosis disease that is resistant in vitro
to the two most highly effective drugs to
treat TB ― rifampicin and isoniazid ― with
or without resistance to other drugs. Treat-
ment requires the use of several harsh sec-
ond-line drugs, including injectables such as
capreomycin, kanamycin, and amikacin.
These drugs have a wide range of severe and
chronic side effects, including hearing loss,
diarrhea, depression, abdominal pain and
nausea, neurapathy, and fatigue [18]. Treat-
ment typically lasts 24 to 27 months and is
25 to 50 times more expensive to treat. Ex-
tensively drug-resistant TB (XDR-TB) can
be defined as resistance to INH and RMP in
vitro, any of the second-line fluoro-
quinolones, and one or more of the second-
line injectable drugs. There is no consensus
on treatment regimen, and XDR-TB is gen-
erally considered untreatable [3].
Historically, drug resistance in TB is a re-
sult of endogenous re-infection, in which in-
complete treatment allows for the genetic
selection of resistant TB strains. Incomplete
treatment may be a result of patient default,
inadequate drug supply, or improper diagnosis
and is largely perpetuated by poor TB health
programs and infrastructures. However, recent
evidence has shown that MDR-TB is now
363Smith: Nanoparticle delivery of anti-TB chemotherapy & drug resistance
Figure 1. Basic structure of M. tuberculosis cell wall. The cell wall of Mtb is comprised
of four layers, making treatment difficult and complex. The outer layer of mycolic acids sur-
rounds inner layers of arabinogalactin and peptidoglycan. These surround the traditional
phospholipid bilayer of the cell.Figure I. 1 The basic stru ture of Mycobacterium tuberculosis cell wall (Smith, 
2017) 
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When M. tuberculosis initially infects the host, the infection phase is 
asymptotic, and this is called the latent phase (Lipworth et al., 2016).  The innate 
immune and adaptive immune system of the human body will react to the bacillus 
invasion (Jacobs et al., 2016), by the development of antibodies and 
macrophage phagocytosis (Delogu et al., 2013; Jacobs et al., 2016).  In the 
latent phase, the innate and adaptive immune system defenses can control the 
reproduction of M. tuberculosis in the lung by macrophages, neutrophils, 
monocytes, dendritic cells, and T cells (Fogel, 2015; Pieters, 2008).  If the 
balance of immune system regulation is disturbed, the growth of M. tuberculosis 
in the host out of control, M. tuberculosis develops new ways to survive under 
immune defense (Pieters, 2008).  The reactivation of dormant M. Tuberculosis 
causes tuberculosis (Venketaraman et al., 2015). The active tuberculosis is also 
called TB disease (Pai et al., 2016).  Patients with TB disease are infectious and 
spread M. tuberculosis through the air.  About 15% of latent tuberculosis cases 
will develop into active tuberculosis during the total lifetime (Connell et al., 2011).  
Another issue with TB disease is that 10% of HIV positive patients are co-
infected with TB (Connell et al., 2011; Sulis et al., 2014).  
I.2 The prevention and treatment of tuberculosis 
Decades of global efforts are developing and discovering new prevention 
and treatment method to eliminate TB transmission and activation (Figure I.2).   
Bacille Calmette-Guérin (BCG) is a vaccine developed from Mycobacterium 
bovis strain.  It was first used in the 1920s (Kaufmann, 2013).  Although the 
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mechanism of BCG is not well identified, it is the only licensed vaccine to against 
TB (Kaufmann, 2013).  Bacille Calmette-Guérin could prevent TB efficiently when 
it is given in infancy or childhood (Sridevi et al., 2015; Venturini et al., 2014).  The 
meta-analysis study shows the protection ability declines after 10 year (Abubakar 
et al., 2013; Alsdurf et al., 2016).  Thus the TB disease occurs in adults and 
adolescents (Tang et al., 2016).  Studies reported new TB vaccines, and some 
TB vaccine candidates are already in clinical tests, such as recombinant BCG 
and vaccine isolated from M. tuberculosis (Chawla et al., 2014; Pai et al., 2016). 
 
 
Figure I.2 Drugs and vaccine development history of TB treatment (Podany and 
Swindells, 2016) 		
The TB treatment drugs include first-line TB agents and second-line TB 
agents.  The first line antituberculosis reagents include isoniazid, rifampicin, 
pyrazinamide, and ethambutol (Wilby et al., 2014).  The second line 
antituberculosis reagents include Amikacin capreomycin, ciprofloxacin, 
cycloserine, ethionamide, kanamycin, ofloxacin, P-aminosalicylic acid and other 
drugs (Nath and Ryoo, 2013).  The cell wall of M. tuberculosis is impermeable to 
Introduction
In 2014, the World Health Organization (WHO) reported 9.6 
million incident cases of tuberculosis (TB), 1.1 million deaths 
from TB among human immunodeficiency virus (HIV)-negative 
people, and an additional 0.4 million deaths from HIV-associated 
TB1. TB is the fifth leading infectious killer of adults worldwide2, 
the third largest killer of women in their reproductive years3, and 
a leading infectious cause of death among people with HIV 
disease2–5. In recent years, the world has seen a rapidly emerg-
ing epidemic of drug-resistant TB, multi-drug-resistant TB, and 
extensively drug-resistant TB, which is lethal and extremely 
expensive and complicated to treat6.
The current first-line four-drug regimen for drug-susceptible TB 
is nearly 50 years old, takes six to nine months to complete, and 
has significant side effects. Treatment for drug-resistant TB may 
take up to 30 months7. Even though more than 250,000 children 
develop TB each year, inexcusably, most anti-TB agents are not 
available in suitable pediatric formulations8. While liquid for-
mulations may be easy to administer to young children, they are 
bulky and more expensive, and some have unacceptable toxicity. 
Only recently have TB drug dosing recommendations been revised 
to reflect differences in the way children metabolize drugs and, 
until recently, most first-line drugs were under-dosed9. Equally 
important, the last 50 years have only brought about the FDA 
licensing of two new drugs for TB treatment (rifapentine and 
bedaquiline) (Figure 1). There is an urgent need for more effective 
and tolerable treatment of drug-susceptible and drug-resistant 
disease and latent TB infection as well as dosing strategies for 
children. Regimens that can be safely co-administered with 
antiretroviral therapy are also needed for the growing number of 
patients co-infected with HIV and TB.
There are some positive developments, though: after a long 
drought, new drugs are available, and new strategies for the 
treatment of latent disease and for regimen development in active 
disease are emerging. A three-month regimen of isoniazid and 
rifapentine has been approved for the treatment of latent infec-
tion in the United States10, and even shorter courses of treatment 
are under study (AIDS Clinical Trials Group [ACTG] study 5279, 
NCT01404312).
New and old rifamycins are being repurposed at optimized 
doses. Clofazimine, an iminophenazine dye used to treat leprosy, 
has attracted renewed interest owing to its ability to target TB. 
Fluoroquinolones have been studied for shorter treatment 
durations of drug-susceptible disease, though phase III trial results 
have been disappointing thus far11. Discussed in more detail below, 
there are novel drugs in new classes approved and/or in clinical 
trials, including bedaquiline, delamanid, pretomanid, AZD5847, 
and sutezolid. Used either separately or in novel combinations, 
these agents are anticipated to shorten and otherwise improve the 
treatment of drug-resistant and, possibly, drug-susceptible TB.
As important as the emerging new strategies for anti-TB regi-
men development are regulatory changes to expedite these efforts. 
Since he 1950s, TB clinical trials have consisted of addition to, or 
substitution of, an existing drug in a standard regimen. Traditional 
trial designs use TB cure without relapse as an endpoint, which 
requires observation for the duration of treatment and then 12–18 
months of follow-up. Therefore, large phase III trials often take 
five or six years to complete and, with multiple compounds now in 
the pipeline, the development of a novel regimen using this model 
would require decades. The recent increase in global philanthropy 
directed at TB and the collaborations amongst major stakeholders 
have created opportunities to overcome bottlenecks and dramati-
cally shorten the time to regimen development. For example, the 
Global Alliance for TB Drug Development, which is a not-for-profit 
product development partnership (PDP), is positioned to leverage a 
global network of public and private partners to advance TB drug 
development by developing drug combinations instead of indi-
vidual drugs12. Treatment shortening remains an important goal for 
Figure 1. Timeline for tuberculosis (TB) drug development. Major milestones in TB drug development over the last century are outlined 
by the date of approval of the drug or intervention. Approval dates for drugs in development are estimated. Abbreviations: BCG, Bacillus 
Calmette-Guérin.
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noxious compounds and drugs.  Many drugs target M. tuberculosis cell walls, 
such as isoniazid, ethambutol, ethionamide and other drugs (Smith, 2017).  
Fluoroquinolones are being considered as new first-line agents (Takiff and 
Guerrero, 2011).  Fluoroquinolones inhibit the function of DNA gyrase in M. 
tuberculosis.  Other drugs inhibit fatty acid biosynthesis, protein biosynthesis, 
DNA based process and other metabolic processes (Janin, 2007).  
The challenge of the treatment of TB is drug-resistant tuberculosis.  Under 
the pressure of drug treatment, M. tuberculosis develops mutations to escape 
death. Drug treatment always fails in these situations.  Drug-resistant 
tuberculosis includes multidrug-resistant tuberculosis (MDR-TB) and extensively 
drug-resistant tuberculosis (XDR-TB).  Multidrug-resistant tuberculosis is 
identified as being resistant to at least two first-line agents, especially isoniazid 
and rifampicin (Mishra et al., 2015).  Extensively drug-resistant tuberculosis is 
identified as MDR-TB plus resistance to at least one fluoquinolone, and at least 
one of the three injectable second-line agents (amikacin, capreomycin, or 
kanamycin) (Jassal and Bishai, 2009).  The mechanisms for drug resistance are 
complex. Mycobactrium tuberculosis develops mutations that lead to drug 
resistance during drug treatment. In isoniazid-resistant M. tuberculosis, mutations 
of gene katG, ahpC, and inhA have been identified (Nath and Ryoo, 2013; Wilby 
et al., 2014).  The katG gene is essential for M. tuberculosis.  It is required for 
converting isoniazid to its active form (Ameeruddin and Luke Elizabeth, 2014).  
Activated isoniazid targets at cell wall and inhibits the synthesis of mycolic acids, 
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which is essential for the cell wall of M. tuberculosis.  Other challenges to TB 
treatment include first-line antituberculosis agents being given to patients for 18 
weeks (Pai et al., 2016).  The first-line drugs are efficient for overcoming 
tuberculosis, but MDR-TB and longtime treatments are challenges to treat 
tuberculosis.  There are urgent needs for new therapeutic drugs to shorten the 
treatment period and kill M. tuberculosis with drug-resistant mutations. 
I.3 DNA topology 
DNA molecules exist in different forms (Dai and Rothma-Denes, 1999; 
Kouzine et al., 2014).  Among these forms, B-DNA molecule is the most common 
form.  B-DNA is a right-handed double helix with 10 base pairs per complete turn 
of the helix (Wang, 1979).  The two-polynucleotide chains are associated by 
hydrogen bonding. They are antiparallel.  Watson and Crick proposed this DNA 
double helix model in 1953.  The DNA double helix model was found in 
physiological conditions by X-ray crystallography by Franklin.  Complementary 
base pairing is featured in this model (Adenine-Thymine, Guanine- 
cytosine)(Figure I.3). 
 
 
Figure I.3 Structure of B-DNA and base pairing.  (Travers and Muskhelishvili, 2015) 
sequence information than the minor groove. How-
ever, importantly, the wide and shallow morphology
of the DNA major groove is in stark contrast to the
narrow and deep structure of the RNA major groove.
This pattern is reversed for the minor groove. For a
protein DNA-binding motif, particularly one contain-
ing an a-helix, access to the DNA major groove is
ore facile than to the minor groove. This fundamen-
tal difference between DNA and RNA follows directly
from their chemical structures. Whereas DNA can
adopt (at least) two forms of right-handed double-heli-
cal structures, A-DNA and B-DNA (Fig. 2A), RNA
can only form an A-type double helix because of the
steric restrictions imposed by the 20 hydroxyl residue
on ribose [9–12]. The B-DNA structure, that proposed
by Watson and Crick [1], is most stable at high humid-
ity, but converts to the A-form as the water activity is
lowered [13]. On this argument, it is the ability to
adopt the B-form that facilitates direct access to DNA
sequence information.
Not only does the A ? B transition affect direct
readout, it also changes the physicochemical proper-
ties of the polymer. An A-type double helix is, on
average, stiffer than a B-type double helix and conse-
quently distortion of A-DNA to a particular bent
configuration is energetically less favourable than for
the corresponding distortion in B-DNA [14]. Such dif-
ferences would be expected to favour B-DNA as the
preferred substrate for packaging involving tight
DNA bending.
Although the formation of a B-type structure is a
crucial aspect of DNA functionality the factors which
shift the A M B equilibrium are, apart from water
activity, poorly understood. One aspect is base-type.
In principle, the coding capacity of DNA can be
achieved not only by the canonical A–T and G–C base
pairs, but also by other possibilities. For example, a
DNA polymer with diaminopurine–thymine (DAP–T)
and hypoxanthine–cytosine (H–C) base pairs with,
respectively, three and two interbase hydrogen bonds
(Fig. 3) would, in principle, present a similar potential
for protein recognition and thermal stability [15].
Other variations would be DNA molecules in which
all the base pairs contain either two or three hydrogen
bonds [16]. However, not only do the component bases
specify a digital code, they also affect the physico-
chemical properties of the molecule. For example,
DNA molecules with a reversed pattern of hydrogen
bonding (DAP–T and H–C base pairs) more readily
adopt an A-type conformation than DNA with the
canonical base pairs [16,17]. This is because the prop-
erties of the double helix depend not only on the base-
pairing capacity of the constituent bases, but also on
the stacking interactions between adjacent base pairs.
Changing base-pairing interactions by effectively trans-
ferring a 2-amino group from guanine to adenine
(thereby creating hypoxanthine and diaminopurine)
changes the overall stacking because the charged 2-
amino group, by being in a different immediate chemi-
cal environment, also affects the dipole moments asso-
A B
(a)
(b)
Fig. 2. (A) Structures of A-DNA and B-DNA. Note the difference in groove width and the relative displacements of the base pairs from the
central axis. Reproduced with permission from Arnott [12]. (B) A–T and G–C base pairs shown for Watson–Crick pairing (a) and Hoogsteen
pairing (b). syn and anti indicated different sugar conformations. Reproduced with permission from Johnson et al. [124].
2281FEBS Journal 282 (2015) 2279–2295 ª 2015 FEBS
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In eukaryotic and prokaryotic organisms, genomic DNA carries coded 
information.  It is crucial for the cellular process to maintain DNA topological 
structure.  The topological structures of DNA molecules change during cellular 
processes (Vologodskii, 2010).  The genomic DNA structures are dynamic and 
flexible.  Some of them link to each other and form different topology states, such 
as DNA knots, and DNA catenates (Figure I.4) (Higgins and Vologodskii, 2015).  
 
Figure I.4 The simple knots and catenanes. (A) Knots. (B) Catenanes. (Higgins and 
Vologodskii, 2015) 	
Another DNA topology state is DNA supercoiling.  It is vital for DNA 
replication, transcription, recombination and repair processes (Magnan and 
Bates, 2015).  Double-stranded DNA crosses the helical axis with two different 
hand directions.  Supercoiling in DNA includes negatively supercoiled DNA and 
positively supercoiled DNA.  Negatively supercoiled DNA is undertwisted and 
responsible for DNA separation (Finzi and Dunlap, 2016).  Positively supercoiled 
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is in the overtwisted state (Travers and Muskhelishvili, 2015).  The topological 
structures of dsDNA change during DNA replication and recombination 
processes (Figure I.5).  Positively supercoiled DNA is generated during the 
transcription process (Baranello et al., 2012).  Other components such as DNA 
polymerases, RNA polymerase, and DNA topoisomerases are required in DNA 
transactions to maintain DNA topological structure (Koster et al., 2010; Seol and 
Neuman, 2016).  
 
 
Figure I.5 The generation of supercoiling during transcription and replication. 
(Baranello et al., 2012) 
 
 
 
(Fig. 1B). This hypothesis applies with minor modiﬁcation to the
movement of transcription and replication complexes as well as for
some helicase and restrictase activities [17–20]. Currently, the best
investigated example is transcription-generated supercoiling. Due to
the overwhelming molecular mass of the RNA polymerase and
given the arguments in favor of immobilization of RNA polymerase
in transcription factories, the DNA template is forced to rotate around
its axis as the double helix threaded through the transcriptional ma-
chinery [21–24]. The upstream DNA becomes untwisted, while the
downstream DNA becomes overtwisted which is referred to as nega-
tively and positively supercoiled, respectively. If the translocation
proceeds without pauses then the RNA polymerase could generate
up to 10 supercoils per second and up to 3000 supercoils for a typical
30 kbp gene [25,26]. This enormous torsional stress might be inhibi-
tory for efﬁcient transcription [17,27,28]. Consequently, it is relieved
by DNA topoisomerases which transiently break and rejoin the back-
bone of DNA [19].
Another source of DNA supercoiling is provided by the reorganiza-
tion of eukaryotic chromatin: the disassembly or assembly of nucleo-
somes releases or absorbs DNA superhelicity. Special protein
complexes called chromatin remodelers are able to remove or slide
nucleosomes in an ATP-dependent fashion [29,30]. Notably, in vitro
experiments have shown that these chromatin remodeling activities
directly generate torsional stress of DNA in the presence of nucleo-
somes [31]. While the remodeling of the chromatin structure is a
broad phenomenon that could involve sometimes entire loci, it is
very difﬁcult to assess and measure in vivo the extent of generated
unconstrained supercoiling due to the transient nature of this process
which could be unsynchronized in a population of cells [32,33]. Con-
sequently, direct evidence are still needed.
In addition to DNA-tracking activities and chromosome remodelers,
the existence of nuclear actins and myosin in principle may allow me-
chanical forces to be applied directly to chromatin ﬁbers [34,35]. Single
DNA molecule experiments in vitro have demonstrated a dynamic cou-
pling between twisting-untwisting of the double helix and stretching
forces, a possibility which remains largely unexplored in vivo [36].
3. Tuning of transcription-generated DNA supercoiling
The level of supercoiling depends on two opposite processes: how
fast torsional stress is introduced into the DNA, and how fast it is re-
laxed or diffused into remote regions of the genome. The supercoil
generation in the DNA ﬂanking RNA polymerase complexes depends
on the rate of transcriptional elongation which may be relatively in-
variant in the absence of speciﬁc RNA polymerase pausing or stalling
and on the rate of transcriptional initiation [17,37,38]. Thus low level
transcription produces a pulse of torsional stress followed by DNA re-
laxation, while high level transcription, due to repetitive initiation,
may establish stable dynamic supercoiling upstream of transcription
start sites [39,40]. In the transcribed unit of highly active genes the
DNA regions between RNA polymerases transcribing in tandem con-
tain supercoils of opposite polarity that could annihilate each other.
Other important parameters include the distribution of promoters
which, in divergent orientation, could reinforce DNA supercoiling up-
stream transcription start sites by untwisting the double helix as well
as by inducing directly plectonemes [41], and the presence or absence
of barriers to diffusion of torsional stress [42]. The dynamics of super-
coil diffusion should depend on the behavior of chromatin ﬁbers: in
principle, the position of individual nucleosomes, the interactions be-
tween them, the linker binding proteins and the nucleosome modiﬁ-
cations will govern supercoil propagation. We still do not knowmuch
about these important properties of chromatin, but single nucleo-
some array experiments in vitro reveal high torsional ﬂexibility of
chromatin compared to naked DNA [15,43]. Successively, it has been
found that chromatin ﬁber behaves qualitatively similar to the nucle-
osome arrays, probably due to the conformational ﬂexibility of
Fig. 1. Basics of DNA topology and its relevance to DNA transactions. The DNA topology is described quantitatively by the twist of double helix and by the number of times the helix
crosses over on itself (plectoneme). Plectonemic structures are typically formed by bacterial plasmids. B) A graphical illustration showing the generation of supercoiling during
transcription and replication. If polymerases are moving without rotation, then due to its helical structure, the DNA must be screwed through the protein complexes. In this
case, the templates rotate a ound its axis as indicated by curved arrows.
633L. Baranello et al. / Biochimica et Biophysica Acta 1819 (2012) 632–638
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I.4 DNA topoisomerases  
I.4.1 Classification of DNA topoisomerases 
James Wang discovered DNA topoisomerase in thr 1970s.  It is called ω 
protein and was isolated from E. coli (Depew et al., 1978).  The DNA 
topoisomerases are essential enzymes that are involved in DNA replication, 
recombination, transcriptional and repair processes.  They regulate DNA 
topology during these processes.  These enzymes are ubiquitous in both 
eukaryotes and prokaryotes.  On the basis of the properties and mechanisms of 
DNA topoisomerases (Table I.1), they are divided into two types: type I 
topoisomerase and type II topoisomerases.   The structure of type I 
topoisomerases is a monomer.  They regulate DNA topology by a single-
stranded DNA passage mechanism.  The DNA type I topoisomerases cleave and 
rejoin a single strand of DNA (Corbett and Berger, 2004).  Type II topoisomerase 
modify DNA topology by a double-stranded DNA passage mechanism, which is 
ATP-dependent. There are three sub-types of type I topoisomerases, type IA 
topoisomerase, type IB topoisomerase and type IC topoisomerase.  Type II 
topoisomerases include type IIA topoisomerase and type IIB topoisomerases 
(Table I.2).  
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Table 1 Key properties of different topoisomerases
Topoisomerase Type
Enzyme
structure
No. of DNA
strands
cleaved
5′ or 3′
bond
formed
Proposed
mechanism
ATP
dependent
Mg(II)
dependent
Activities
Catenation/
decatenation
Knotting/
unknotting
Relaxation Supercoiling
−veb +veb −ve +ve
Topo I Bacterial IA Monomer 1 5′ Strand passage No Yes Yesc Yesc Yes No No No
Eukaryotic IB Monomer 1 3′ Controlled
rotation
No No Yesc Yesc Yes Yes No No
Topo II IIA Homo-dimer 2 5′ Strand passage Yes Yes Yes Yes Yes Yes No No
Topo III IA Monomer 1 5′ Strand passage No Yes Yesc Yes Yes No No No
Topo IV IIA Hetero-tetramer 2 5′ Strand passage Yes Yes Yes Yes Yes Yes No No
Topo V IB/ICa Monomer 1 3′ Controlled
rotation
No No Unknown Unknown Yes Yes No No
Topo VI IIB Hetero-tetramer 2 5′ Strand passage Yes Yes Yes Unknown Yes Yes No No
DNA gyrase IIA Hetero-tetramer 2 5′ Strand passage Yes Yes Yesd Yes Yes Yes Yes No
Reverse gyrase IA Monomer 1 5′ Strand passage Yes Yes No No Yes No No Yes
aTopo V was originally described as type IB but has been proposed to form a new class (IC).
b-ve indicates negatively supercoiled DNA; +ve indicates positively supercoiled DNA.
cPossible only if one substrate is nicked or single stranded.
dDecatenation by E. coli DNA gyrase is weak.
A
S
M
S
cience.org/EcoS
alPlus
5
DN
A
Topoisom
erases
Table I.1 Basic tructure, mechanism and properties of different DNA topoisomerases (Bush et al., 2015) 
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Type IA 
topoisomerases 
Bacterial and archael DNA topoisomerase I 
and III 
Yeast DNA topoisomerase III  
Mammalian DNA topoisomerase IIIα and IIIβ  
Type IB topoisomerases Eukaryotic DNA topoisomerase I  
Mammalian mitochondrial DNA 
topoisomerase I 
Pox virus topoisomerase  
Type IC 
topoisomerases 
Methanopyrus topoisomerase V (Archael)  
Type IIA 
topoisomerases 
Bacterial gyrase and DNA topoisomerase IV 
Yeast DNA topoisomerase II  
Mammalian DNA topoisomerase IIα and IIβ  
Type IIB 
topoisomerases 
Sulfolobus shibatae topoisomerase VI  
Table I.2 Subfamilies of DNA topoisomerases (Wang, 2002) 
	
The DNA topoisomerases cleave single or double-stranded DNA.  The 
active site tyrosine of DNA topoisomerases attack the phosphate in the DNA 
backbone, an enzyme-DNA intermediate complex forms at the same time.  In the 
intermediate forming process, the 3’-hydroxyl group of DNA leaves the DNA 
backbone, and the active site tyrosine of type IA and type IIA topoisomerases 
covalently links to the 5’-phosphate to form a phosphotyrosyl bond (Pommier, 
2013).  Whereas the active site tyrosine of type IB topoisomerase attacks the 
phosphate of the DNA group to form a 3’-phosphotyrosyl bond (Pommier, 2013; 
Wang, 2002). 
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Figure I.6 Catalysis of transient breakage of DNA by type IA DNA topoisomerases 
(Wang, 2002).  		
I.4.2 Type II topoisomerases 
Type II topoisomerases are essential enzymes for all organisms.  Type IIA 
topoisomerases include bacterial DNA gyrase, topoisomerase IV and eukaryotic 
topoisomerase II.  They cleave double-strand DNA in a DNA duplex and process 
DNA strand passage (Gentry and Osheroff, 2013).  All Type II topoisomerases 
can catenate/decatenate, knot/unknot circular duplex DNA, and relax positively 
and negatively supercoiled DNA (Figure I.7).   They are important for maintaining 
the stability of the DNA topological structure.  In vertebrate species, 
Topoisomerase IIα (TOPIIα) and Topoisomerase IIβ (TOPIIβ) are two kinds of 
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R E V I EW S
NEGATIVELY AND POSITIVELY
SUPERCOILED DNA 
A loop of a double-stranded
DNA segment will become
contorted if one end of it is
turned around its helical axis at
that end while the other end is
kept stationary in space (much
like the spatial coiling of a
rubber tubing when similarly
handled). The number of
supercoils that are introduced
into this loop is a parameter that
is used to quantify the distortion
of the looped DNA segment; one
negative supercoil is said to be
introduced into the DNA loop
by each full turn of the rotating
end in the direction that tends to
unwind the right-handed double
helix; one positive supercoil is
said to be introduced by each full
turn of the rotating end in the
direction that tends to overwind
the right-handed double helix.
DNA ends relative to each other mediate the opening
and closing of the DNA gate7.
Type IB. The type IB enzymes are thought to act by a
‘DNA rotation’, rather than by an enzyme-bridging,
mechanism3.When a DNA-bound type IB enzyme (FIG.2b)
transiently cleaves one of the DNA strands, only the side
of the DNA double helix that is upstream of the nick —
the side containing the protein-linked 3′ end of the bro-
ken strand — is tightly bound to the enzyme.
Interaction between the downstream side of the dsDNA
and the enzyme is mostly ionic in nature, so it presents a
low barrier to rotation between the DNA and protein3.
The DNA segments that flank a transient nick can there-
fore rotate relative to each other by turning around one
of the single bonds that opposes the nick3.
The type IB enzymes are very efficient at relaxing
both positively and negatively supercoiled DNA.
Although catenation or decatenation of nicked dsDNA
rings by a type IB enzyme in vitro has been reported8, it
remains unclear how the enzyme carries out intermole-
cular strand passage. A linear dsDNA intermediate, with
the enzyme covalently linked to one end of it, could be
formed in such a reaction; if so, these reactions are prob-
ably not significant in vivo.
There is another mechanistically important difference
between the two type I enzymes. In the type IA-enzyme-
catalysed reactions, breakage and rejoining of the DNA
strand occur in a single-stranded region1,4,5. In the reac-
tions that are catalysed by the type IB enzymes, the nick
is generated in a dsDNA segment3. Cleavage by a type IB
enzyme in the single-stranded region of a dsDNA with a
single-stranded gap could occur, but the 5′ end of the
transiently broken DNA might readily detach from the
enzyme, yielding a linear DNA intermediate.
Type II. In contrast to the type IA and type IB
enzymes, the type IIA and IIB DNA topoisomerases
catalyse the ATP-dependent transport of one intact
DNA double helix through another1–3,9. Before the
first type IIB enzyme was identified in the archaeon
Sulfolobus shibatae10, all type II DNA topoisomerases
were thought to belong to a single subfamily. It is now
clear that both type IIA and type IIB DNA topoiso-
merases are widely distributed11 (BOX 1). FIGURE 2c
depicts a molecular model for the transport of one
DNA double helix through another by a type IIA
enzyme9,12. The less-extensively studied type IIB
enzymes share several common mechanistic features
with the type IIA enzymes10, but there are distinct
structural differences between the two subfamilies13.
The ATP-dependent transport of one DNA double
helix through another by a type II DNA topoisomerase
is manifested in several topological transformations,
including catenation and decatenation of dsDNA rings,
and the relaxation of positively or negatively super-
coiled DNA1–3,9,12. The relative efficiencies of a given
type II enzyme in catalysing these reactions depend on
the structural features of the DNA substrates and the
enzyme–DNA complexes. Bacterial gyrase (DNA
topoisomerase II), for example, is unique in that a
Reactions catalysed by topoisomerases 
Type IA. In t  relaxati n f n underwound or NEGATIVELY
SUPERCOILED DNA by a type IA enzyme, a short stretch
of double-stranded (ds)DNA is first unpaired by the
binding of the enzyme, and a transient break is
introduced in this single-stranded region1,4,5. The less
negatively supercoiled the DNA is, the more difficult
it is for the enzyme to unpair the dsDNA; and so, the
proficiency of the enzyme progressively decreases
during the course of the reaction. Overwound or
POSITIVELY SUPERCOILED DNA is refractive to the type IA
enzymes unless a pre-existing single-stranded region
is present5.
The type IA DNA topoisomerases can also pass one
DNA double helix through another if at least one of the
pair contains a nick or gap6; in this reaction, an enzyme
probably introduces a transient break across from the
nick or gap. The type IA enzymes are believed to catal-
yse DNA strand passage by an ‘enzyme-bridging’ mech-
anism (FIG. 2a), in which the DNA ends that are created
in the DNA breakage reaction are bridged by the topoi-
somerase1,7,8, and movements of the enzyme-bound
OH O
O DNA
P
O
–OO DNA
P
O
O–O
DNA
OH
DNA5′
3′
3′
5′
3′
Figure 1 | Catalysis of transient breakage of DNA by DNA
topoisomerases. Transesterification between an enzyme
tyrosyl and a DNA phosphate group leads to the breakage of 
a DNA backbone bond and the formation of a covalent
enzyme–DNA intermediate. Rejoining of the DNA backbone
bond occurs by the reversal of the reaction shown. In the
reaction that is catalysed by a type IA or a type II enzyme, 
a 3′-OH is the leaving group and the active-site tyrosyl
becomes covalently linked to a 5′-phosphoryl group, as
depicted. In the reaction that is catalysed by a type IB enzyme
(not shown), a 5′-OH is the leaving group and the active-site
tyrosyl becomes covalently linked to a 3′-phosphoryl group.
Table 1 | Subfamilies of DNA topoisomerases
Subfamily Representative members
IA Bacterial DNA topoisomerases I and III
Yeast DNA topoisomerase III
Drosophila melanogaster DNA topoisomerases IIIα and IIIβ
Mammalian DNA topoisomerases IIIα and IIIβ
IB Eukaryotic DNA topoisomerase I
Mammalian mitochondrial DNA topoisomerase I
Pox virus topoisomerase
IIA Bacterial gyrase, DNA topoisomerase IV
Phage T4 DNA topoisomerase
Yeast DNA topoisomerase II
Drosophila DNA topoisomerase II
Mammalian DNA topoisomerases IIα and IIβ
IIB Sulfolobus shibatae DNA topoisomerase VI
(subunit A homologous to yeast Spo11)
© 2002 Nature Publishing Group
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type IIA topoisomerases (Gentry and Osheroff, 2013). Topoisomerase IIα is 
involved in the survival of proliferating cells during the cell cycle.  The enzyme 
topoisomerase IIβ participates in the neural development.  Type IIA 
topoisomerases are clinical therapeutic targets for anticancer and antibacterial 
drugs.  These drugs include poison and catalytic inhibitors (Nitiss, 2009).  
Quinolones are broad-spectrum antibacterial drugs.  As well as first line 
antituberculosis drugs.  Quinolones are poison inhibitors, which target DNA 
gyrase.  Amsacrine, etoposide, and doxorubicin are poison anticancer drugs, 
which target human type II topoisomerases (Pommier et al., 2010). 
       
Figure I.7 Catalytic reactions of type II topoisomerases (Bush et al., 2015) 
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DNA supercoiling can be either positive (correspond-
ing to over-twisting of the helix) or negative (corre-
sponding to under-twisting of the helix). The binding
of proteins to DNA is often dependent on the DNA
being negatively supercoiled; initiation of the replica-
tion of bacterial plasmids requires negative supercoiling
to facilitate the unwinding of the origin sequence (8).
As DNA replication proceeds, positive supercoils are
generated ahead of the replication fork and so-called
precatenanes may build up behind it (Fig. 3) (9). The
supercoils are removed by topoisomerases to prevent ex-
cess supercoiling and the breakdown of the replication
machinery.
When two replication forks converge at the end of DNA
replication, catenated DNA rings can be formed if the
daughter molecules are interwound; i.e., precatenanes are
converted to catenanes (Fig. 4) (10, 11). These rings can
be separated by decatenation, in which one DNA ring is
cleaved and the other ring is passed through the double-
strand break. As discussed below, this situation can be
resolved by the activities of various topoisomerases.
Transcription may also result in changes to DNA topol-
ogy, for example, if the DNA is anchored to a fixed point
in the cell. It has been proposed that during transcrip-
tion DNA rotates on its axis to allow RNA polymerase
Figure 2 Reactions performed by type II topoisomerases. Examples of specific type II topoisomerases that catalyze the indicated reactions are
given above the arrows. It is important to note that in the decatenation/catenation reaction, the plasmids may be supercoiled before decatenation/
catenation occurs; for illustrative purposes they have been drawn as relaxed. Although only relaxation of negative supercoils is shown, all known
type II topoisomerases can relax positively supercoiled DNA as well. (Redrawn from reference 313 with permission of the publisher.) doi:10.1128/
ecosalplus.ESP-0010-2014.f2
ASMScience.org/EcoSalPlus 3
DNA Topoisomerases
	 14	
Type II topoisomerases function as homo-dimers. Eukaryotic type II 
topoisomerases are dimeric (A2), and prokaryotic type II topoisomerases are 
tetrameric (A2B2) (Berger and Wang, 1996).   Yeast type II topoisomerase is 
(BA)2 homo-dimers.  Type II topoisomerases have three interfaces, N-gate, DNA-
gate, and C-gate (Figure I.8). The catalytic process of type II topoisomerases is 
ATP-dependent.  Briefly, they bind a double-stranded DNA (G segment), cleave 
it and let the second double-stranded DNA (T segment) through the cleaved 
double-stranded DNA.  Two ATP molecules are required for the hydrolysis 
process (Gentry and Osheroff, 2013).  Magnesium is also needed for catalysis.  
The enzyme DNA gyrase is bacterial topoisomerase II (Lee et al., 2012).  Two 
GyrA and two GyrB subunits form the DNA gyrase.  Escherichia coli DNA gyrase 
is about 400 kDa.  The GyrB and GyrA subunits of DNA gyrase are homologous 
to the N- and C-terminal halves of eukaryotic topoisomerase II, respectively.  The 
tyrosine active site of DNA gyrase is in the GyrA subunit.  ATP molecule binds to 
N-terminal of eukaryotic topoisomerase II and GyrB subunit of DNA gyrase.  
There are identified as ATPase domains, which use ATP binding and hydrolysis 
to promote strand passage mechanism in S. cerevisiae topoisomerase II 
(Schmidt et al., 2012). 
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Figure I.8 Crystal structure of S. cerevisiae type II topoisomerase (Basu et al., 
2016). 	
I.4.3 Type I topoisomerases 
All organisms contain at least one type I topoisomerase.  They have the 
ability to relax, unknot/knot or decatenate/catenate single-stranded DNA or 
double-stranded nicked DNA with a gap in one of the strand (Figure I.8) (Forterre 
and Gadelle, 2009).  Type I topoisomerases include type IA topoisomerase, type 
IB topoisomerase and type IC topoisomerase.  Type IA topoisomerase can relax 
negatively supercoiled DNA.   Type IB topoisomerase relaxes positively and 
negatively supercoiled DNA.  Type I topoisomerase requires Mg2+ in the 
relaxation process.  
visited during the mechanochemical cycle, and
characterize transitions in this global architecture
dependent on substeps in fuel consumption.
A recent cryoelectron microscopy study [21]
provides the most complete picture to date of the
architecture of full-length DNA gyrase, and the first
direct visualization of DNA wrapped around the
CTDs (Fig. 2a). A 23 Å map of the T. thermophilus
gyrase holoenzyme was obtained in complex with
155 bp DNA, stabilized with ciprofloxacin and
AMPPNP. The N-gate is closed and the CTDs are
in plane with the DNA gate, with clear density
attributable to DNA bent around them. The confor-
mation was proposed to represent a state that traps
a T-segment prior to strand passage, although the
included DNA appears to be of insufficient length to
present a T-segment in the complex that was
obtained. The modeled DNA (Fig. 2a) includes a
shallower G-segment bend than has been seen in
crystal structures of various type IIA topoisomerases
in complex with DNA (Fig. 2b), including structures of
the gyrase cleavage core bound to shorter DNA
fragments [4, 5], suggesting an influence of the
CTDs on the central DNA conformation. The authors
also obtained a 17 Å reconstruction of the holoen-
zyme in the absence of DNA, in which the CTDs are
not visible due to conformational heterogeneity. For
both reconstructions, the closed N-gate is seen in a
“domain swapped” configuration previously ob-
served [22] in a recent structure of the full length
S. cerevisiae topoisomerase II in complex with
G-segment DNA and AMPPNP (Fig. 2b), which was
Fig. 2. Recent structures illuminate the architectures of gyrase and related type II topoisomerases. (a) 23 Å CryoEM
map of the T. thermophilus gyrase holoenzyme in complex with 155 bp DNA, ciprofloxacin, and AMPPNP (reproduced
from [21]). The domain architecture can be seen together with density attributable to DNA wrapped around the CTDs.
Crystal structures of protein components and modeled DNA duplex (green) have been fit to the density. The closed N-gate
is shown in a domain-swapped configuration first observed in (b) a crystal structure (reproduced from [22]) of the related
enzyme S. cerevisiae topo II in complex with G-segment DNA (green) and AMPPNP. The DNA-gate and the C-gate are
also seen in closed configurations in these structures.
1835Review: Dynamics and Coupling in DNA Gyrase
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Figure I.9 Catalytic reactions of type I topoisomerases (Bush et al., 2015) 
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reaction. The reactions performed by DNA topoisomer-
ases are depicted in Fig. 1 and Fig. 2. It should be pointed
out that many enzymes (e.g., ligases and recombinases)
can affect DNA topology but are not referred to as topo-
isomerases, which is a term reserved for enzymes whose
specific role is manipulation of DNA topology. Similarly,
there may be enzymes currently classified as topoisom-
erases (e.g., topoisomerase III [topo III] and reverse
gyrase) whose principal cellular function may be another
activity.
Figure 1 Reactions performed by type I topoisomerases. Examples of specific type I topoisomerases that catalyze the indicated reactions are
given above the arrows. It is important to note that in the decatenation/catenation reaction, the non-nicked plasmid may be supercoiled before
decatenation/catenation occu s; for illustrative purposes it has been drawn as relax d. (Adapted from reference 313 with permission of the
publisher.) doi:10.1128/ecosalplus.ESP-0010-2014.f1
2 ASMScience.org/EcoSalPlus
Bush et al.
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Type IB topoisomerases are present in all eukaryotic organisms. Animal 
virus topoisomerase I and mammalian mitochondrial topoisomerase I belong to 
the type IB topoisomerase family (Patel et al., 2010).  Type IB topoisomerases 
relax duplex DNA by a “controlled rotation mechanism’’.  They nick a single-
stranded DNA and allow the DNA strands to rotate around each other (Forterre 
et al., 2007).  Type IB topoisomerases participate in replication, transcription, 
repair, and chromatin modification processes.  They also target anticancer drugs 
including topotecan and irinotecan (Capranico et al., 2017).  
Type IA topoisomerases regulate DNA topology by a cleavage and strand 
passage mechanism.  During the cleavage and religation process, one single 
strand of DNA is cleaved, and the other single strand of DNA pass the gap at the 
strand break.  A covalent intermediate of DNA and enzyme forms in the cleavage 
process and disappears in the religation process.  There is a conformational 
change of the enzyme during this process (Figure I.10).  The type IA subfamily 
include bacterial DNA topoisomerase I, bacterial DNA topoisomerase III, 
eukaryotic DNA topoisomerase III and reverse gyrase (Table I.2).  Bacterial type 
IA topoisomerases are classified to relax only negatively supercoiled DNA with 
Mg2+ requirement.  As type IA topoisomerase, bacterial topoisomerase I is 
considered as a potential target for antibacterial drugs (Tse-Dinh, 2009). 
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Figure I.10 Proposed mechanism of type IA topoisomerase (Terekhova et al., 2013) 
 
In type IA topoisomerases, the tyrosine active site is in the NTD.  The N-
terminal domain of type IA topoisomerase has the DNA binding, cleavage and 
religation activity.   The N-terminal domain of type IA topoisomerases is 
conserved within bacterial topoisomerases and includes the topoisomerase-
primase domain (TOPRIM) (Aravind et al., 1998).  However, the CTD is variable 
within bacterial species (Figure I.11).  Escherichia coli topoisomerase I (EcTOP I) 
contains three tetracysteine zinc ribbon motifs in its CTD.   These Zn2+ binding 
domains include Cys-X2-Cys-Gly-X2-Met-X12-13-Cys-X4-10-Cys sequence (Tse-
Dinh and Beran-Steed, 1988).  The Zinc ribbon motifs are essential for the 
activity of E. coli topoisomerase I are proposed to bind to DNA and facilitate 
stand passage.  If these cysteine amino acids are mutated, EcTOP I loses 
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Figure 2 Proposed mechanism of DNA relaxation catalysed by type IA topoisomerases
Proposed mechanism employed by type IA enzymes to relax DNA [10,14]. The conformations of many of the different
intermediates are based on solved structures, but some intermediates have not been observed and remain hypothetical.
Many of the features of the proposed mechanism have been confirmed through biochemical, structural and single-molecule
experiments. ssDNA, single-stranded DNA.
in different cellular processes. In vivo, a major function
of topoisomerase I, together with two type II enzymes
(topoisomerase IV and gyrase), is to maintain the supercoiled
state of DNA in the cell [21]. The function of topoisomerase
III, the other type IA enzyme, is to resolve single-stranded
DNA recombination and replication intermediates [22–27],
and, in some instances, double-stranded intermediates [28].
These differences in functions are reflected in their in vitro
characteristics: topoisomerase I is a better DNA relaxation
enzyme than topoisomerase III [22], whereas topoisomerase
III is a better decatenating enzyme [29,30]. From a structural
perspective, the two enzymes are also different in subtle
ways. The major difference between the two is the presence
of a much larger C-terminal domain in topoisomerase I
that is involved in DNA binding and is essential for DNA
relaxation activity [11,12], whereas the C-terminal domain
of topoisomerase III also binds DNA, but is smaller and
dispensable [31]. Another small, but significant, difference is
the presence in topoisomerase III of a 17-amino-acid region,
termed the decatenation loop, that resides at the base of
the central hole and whose removal decreases decatenation
activity markedly [32].
Single-molecule studies of type IA
topoisomerases
Biochemical experiments have been instrumental to study
topoisomerases and to understand their differences and
similarities. Nevertheless, experiments in bulk can hide some
details by the inevitable averaging that occurswhen looking at
billions of molecules at a time. For this reason, it is important
to look at the action of topoisomerases at the single-molecule
level. Single-molecule studies of type I topoisomerases have
been very informative andhave helped touncover newaspects
of the mechanism of these enzymes [33]. Type IA enzymes
were among the first topoisomerases to have been studied
at the single-molecule level, and these studies confirmed
the enzyme-bridged strand passage mechanism [19]. More
recently, studies of eukaryotic type IB topoisomerases
revealed some of the constraints imposed by the protein
on the swivelling of the DNA strands and also helped us
to understand the role of some topoisomerase poisons [34–
36]. Finally, single-molecule studies were essential to clarify
the mechanism of topoisomerase V, the sole member of the
type IC group [37].
In order to understand the mechanistic difference between
the two E. coli type IA topoisomerases, we analysed DNA
relaxation by the two enzymes at the single-molecule level
using a magnetic tweezers set-up [38]. In this type of
experiment, one end of a long single DNA molecule is
attached to a functionalized glass slide while the other end
is attached to a small (∼1–3 µm) paramagnetic bead. By
using a rotating magnet, it is possible to introduce supercoils
into the DNA at will while monitoring the position of the
bead through a microscope. Rotating the magnet causes the
DNA to over- or under-wind, and eventually plectonemes
are formed in the single DNA molecule [39]. This is always
the case for positively supercoiled or overwound DNA,
C⃝The Authors Journal compilation C⃝2013 Biochemical Society
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activity. Streptomyces topoisomerase I CTD contains lysine repeats and end with 
acidic amino acids. Other bacterial topoisomerase I also contain lysine repeats 
with different position and sequence length (Strzalka et al., 2017).  The lysine 
repeats in Streptomyces topoisomerase I are able to stabilize the topoisomerase-
DNA complex and maintain the enzyme processivity.  The CTD in Streptomyces 
topoisomerase I is responsible for DBA binding and the cellular growth of 
Streptomyces. 
 
 
 
Figure I.11 Comparison of topoisomerase I sequences from various bacterial 
species. N-terminal domain (blue); C-terminal domain (red); TOPRIM domain (purple) is 
conserved in NTD; the catalytical tyrosine residue (black); Zinc ribbon motifs (yellow); 
lysine repeats (red) (Strzalka et al., 2017). 
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I.4.4 The cellular function of DNA topoisomerases 
DNA topoisomerases affect DNA replication, transcription, recombination, 
and repair at the cellular level (Chen et al., 2013; Wang, 2002).  It is reported that 
DNA topoisomerases play an important role in all the steps of replication, in 
initiation, elongation, and termination (Wang, 2002).  In E. coli, DNA 
topoisomerase III’s strand passage function controls the DNA recombination 
mechanism (Harmon et al., 1999).  The replication process is initiated from 
specific supercoiled origins in both eukaryotes and prokaryotes (Wu et al., 2014).  
Eukaryotes activate replication by loading origin recognition complex to 
chromatin (Parker et al., 2017).  Topoisomerases are needed to work with 
specific origins to control replication initiation (Magnan and Bates, 2015; 
Rampakakis et al., 2010; Vos et al., 2011).  In the DNA elongation step, 
replicative helicase progress brings overwinding and potential distortion positive 
helical stress to the DNA duplex.  In the eukaryote, type II and type IB 
topoisomerases are able to remove positively supercoiled DNA ahead of the 
replication fork (Keszthelyi et al., 2016).  Topoisomerase III is also observed to 
support the nascent chain elongation during DNA replication in E. coli (Hiasaand 
and Marians, 1994).  The new precatenanes are resolved by type II 
topoisomerases (Figure I.12).  If two replication forks are too close, the two 
precatenates form a hemicatenane.  Topoisomerase III is able to resolve this 
topological state with RecQ and stablilize the DNA topology (Nurse et al., 2003; 
Suski and Marians, 2008).  In yeast cells, topoisomerase II mediated replication 
termination by segregation of chromosomes (Bailey et al., 2015; Dinardo et al., 
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1984; Fachinetti et al., 2010). 
The enzyme RNA polymerase and its bounded proteins regulate 
transcription process.  In the elongation step of transcription, the DNA topology is 
dynamic and stressful.  Positive DNA supercoiling is generated ahead of the 
elongating RNA polymerase, and negatively supercoiled DNA is released or 
rearranged behind the transcription company (Kouzine et al., 2014).  The DNA 
topoisomerases are required to stabilize the DNA topology and remove the 
topological stress by interacting with DNA (Keszthelyi et al., 2016).  In E. coli, 
gyrase is observed to bind positively supercoiled DNA to start transcription 
(Chong et al., 2014).  In eukaryotic cells, Type IB and type II topoisomerases are 
able to remove positively supercoiled DNA in this step.  Both type I and type II 
topoisomerase are able to relax the negatively supercoiled DNA for transcription 
elongation (Vos et al., 2011; Wang, 2002).  A current study shows that DNA 
topoisomerase I interacts with RNA polymerase via a 27 amino acid tail in its 
CTD in M. smegmatis (Banda et al., 2017).  These interactions enable DNA 
topoisomerase I in M. smegmatis to work with RNA polymerases in the 
transcription process.  
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Figure I.12 Topoisomerase function in replication elongation. (Vos et al., 2011) 
 
I.5 Bacterial topoisomerase I 
I.5.1 E. coli type IA topoisomerases 
Escherichia coli topoisomerase I is the first discovered and well-studied 
topoisomerase.  The 67 kDa NTD of EcTOP I is required in its DNA cleavage and 
religation activity (Ahumada and Tse-Dinh, 2002).  Both ssDNA and dsDNA 
could interact with EcTOP I.  It was also observed to have catenation and 
decatenation activity (Ahumada and Tse-Dinh, 2002; Terekhova et al., 2014).  
The NTD of EcTOP I contains active site and DNA interaction region with active 
site tyrosine (Y319) and TOPRIM motif (Narula and Tse-Dinh, 2012).  Without 
the DxD TOPRIM motif, the Mg2+ binding ability of EcTOP I decreased (Cheng et 
al., 2009).  The TOPRIM mutation affected religation activity.  Thus the DNA-
topoisomerase covalent complex was trapped.  As a Zn2+ binding protein, the 
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CTD of EcTOP I contains three repetitive Zinc ribbon domains (Lu et al., 2011; 
Tse-Dinh and Beran-Steed, 1988).  The C-terminal domain of EcTOP I binds to 
ssDNA but not dsDNA.  It also interacts with RNA polymerase in transcription 
process (Cheng et al., 2003).  The crystal structure of EcTOP I with ssDNA 
revealed that the Zinc ribbon motifs bind to ssDNA (Figure I.12) (Tan et al., 
2015).  As mentioned, E. coli topoisomerase III (EcTOP III) plays an important 
role in DNA recombination. Escherichia coli topoisomerase III catenates 
covalently closed DNA and interacts with helicase (Harmon et al., 2003). 
Escherichia coli topoisomerase III also decatenates catenated both dsDNA and 
ssDNA with RecQ (Suski and Marians, 2008).  Kinetic studies revealed that the 
decatenation activity of EcTOP III is more efficient than that of EcTOP I 
(Terekhova et al., 2014). Escherichia coli topoisomerase III contains a 
decatenation loop in its CTD.  While EcTOP I is more efficient for DNA relaxation 
(Terekhova et al., 2012).  Different structures of these two topoisomerases lead 
to different pathways in their catalytic activities.  The NTD is conserved (Figure 
I.13).  Subdomain I contains the TOPRIM motif. Active site tyrosine is in 
subdomain III (D3).  Unlike EcTOP I, EcTOP III has a short CTD without Zn2+ 
binding domains (Terekhova et al., 2013).  
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Figure I.13 Structures of EcTOP I and EcTOP III.  (A) The organization of EcTOP I and EcTOP III.  (B) The crystal 
structure of EcTOP III.  (C) The crystal structure of EcTOP I and DNA complex (Schoeffler and Berger, 2008; Tan et 
al., 2015)
Fig. 6. Type IA topoisomerase organization and structure. (a) The primary domain structures of E. coli
topoisomerase I and III (type IA topoisomerases). Domains are indicated by color and labeled catalytic
residues are shown as black bars. (b) Structure of E. coli topoisomerase III complexed with DNA. Domains
are colored as in (a). Bound DNA is colored by atom and shown as sticks. The catalytic tyrosine (Y, cyan
sphere) is located at the domain III–domain I interface. (PDB ID 1I7D) (Changela et al. 2001). (c) Rotation
of the structure in (b) by 90x reveals the decatenation loop projecting from the ‘back ’ of the enzyme. (PDB
ID 1I7D) (Changela et al. 2001). (d) Close-up view of the E. coli topo III active site in the absence of DNA.
Protein is colored by domain as in (b). The active site tyrosine forms hydrogen bonds with two conserved
aspartates (PDB ID 1D6M) (Mondragon & DiGate, 1999). (e) Close-up of the active site of E. coli topo-
isomerase III bound to DNA in a ‘pre-cleavage ’ conformation. Protein is colored as in (b). DNA is colored
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Figure 1. Structure of full-length E. coli topoisomerase I (EcTOP1) in
complex with single-stranded DNA (ssDNA). (A) Domain arrangement
of E. coli topoisomerase I. Between D8 and D9, there is a helical hair-
pin. (B) A ribbon diagram of full-length EcTOP1 in complex with ssDNA.
Full-lengthEcTOP1 includes fourN-terminal domains:D1 (deep salmon),
D2 (orange), D3 (cyan) and D4 (green); and five C-terminal domains: D5
(pink), D6 (yellow), D7 (red), D8 (lime) and D9 (grey). The helical hairpin
between D8 and D9 is colored in wheat. A ssDNA that binds to the C-
terminal domains is colored in blue. Each Zn(II) is represented as a gray
sphere. The secondary structures of D2 and part of D4 and D6 are la-
beled for discussion purposes. A part of the loop (colored in green) be-
tween !2 and "6 of D2 includes a charged and conserved sequence of
R442KGDEDR, which is highly flexible and was not observed in earlier
TOP67 structures. Figures 1B, 2, 4 and 7A are prepared with the program
PyMOL (http://www.PyMOL.org).
served. The conformation of the active site of the enzyme,
which includes residues D111, D113, Y319 and R321 from
D1 and D3 are essentially the same (Supplementary Fig-
ure S2). However, if all four N-terminal domains were used
for an alignment, the RMSD value is as high as 1.84 A˚,
which indicates domain-domain movements between the
two structures. Therefore the presence of the C-terminal do-
mains with bound ssDNA may have an effect on the con-
formation of the toroid formed by the N-terminal domains.
The largest change involves D2 that rotates (∼14◦) away
from the N-terminal domains’ toroidal plane (Supplemen-
tary Figure S3).
A loop between the !2 helix and the "6 strand of D2,
which was mostly disordered in previous TOP67 structures,
can now be observed in this structure (Figure 1). The flex-
ible portion of the loop comprising of a charged sequence,
R442KGDEDR, extends into the center of the toroid hole
and might have an important role in the proposed route of
the passing strand in the DNA relaxation catalyzed by the
enzyme. The corresponding region in other bacterial topoi-
somerase I sequences are also rich in charged residues (Sup-
plementary Figure S4). In the structure of E. coli topoi-
somerase III, a similarly charged loop, R454RDEEND, is
also present (40). It is possible that the structural ordering
of the charged loop aswell as the rotation ofD2 as described
above in the full-length EcTOP1 may be related to the pres-
ence of C-terminal domains and/or DNA binding to the
C-terminal domains as elaborated below.
TOP30C 4-Cys zinc ribbon domains and zinc ribbon-like do-
mains
The first three TOP30C domains (D5–D7) are 4-Cys zinc
ribbon domains (Figure 2A). Each domain comprises a 4-
stranded antiparallel "-sheet with a Zn(II)-binding site on
the top of the domain. The Zn(II) ion is coordinated by four
conserved cysteines from the "1-"2 and "3-"4 loops (Fig-
ures 2B and 3). This is consistent with earlier predictions
based on sequence homology and biochemical data (16,17).
The presence of zinc at the metal-binding site of each do-
main is confirmed by anomalous differencemaps calculated
from diffraction data collected at the zinc absorption peak
(Figure 2A–B, Table 1). The presence of the Zn(II) ions in
three 4-Cys zinc ribbon domains of EcTOP1 is in contrast
to the absence of Zn(II) in the 4-Cys zinc ribbon domain in
the structure of Thermotoga maritima topoisomerase I (41).
The four cysteines in the latter structure unexpectedly form
two disulfide bonds instead. Beneath the Zn(II)-binding site
of each domain there are a conserved methionine from the
"2 strand and a hydrophobic residue from the "3 strand
(Figure 3). These two residues seemingly form the core of
the small 4-Cys Zn ribbon domain (Figure 2B). D5 has a
one-residue "− bulge in the middle of its "1 strand (not
shown in figures) while D6 has an unusual 21-amino acids
insert in the middle of the first strand. A part of the insert
forms a unique !-helix (!1) (Figures 1, 2A and 3), which
interacts with TOP67 and is elaborated below. One unique
feature of D7 is that it has an extra short "5 strand (Fig-
ure 2B).
D5 makes few contacts with D4. There are only one hy-
drogen bond contributed by the first residue of D5 (Q591)
to D4 and a few van der Waals contacts between D5 and
TOP67. However, it is D6 that forms extensive interactions
with TOP67, mostly through its unique helix (!1 of D6)
(Figure 1). The interactions involve TOP67’s D2 and D4
and the hinge between them. A movement of the !1 helix
or D6 itself against the hinge (e.g. a push or a pull) will
cause the rotation of D2 in respect to D4. The change in
relative orientation of two N-terminal domains could play
a role in the control of the opening-closing state of the
toroid hole, suggesting a possible EcTOP1 activity regu-
lation by a TOP30C movement. Additionally, D5 and D6
adopt an unusual conformation with their "-sheets being
packed against each other (Figure 2C). The interface of the
two domains is rich in hydrophobic residues (Figure 2C);
the movement of D5 and D6 may therefore be highly coor-
A	
B
C	
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I.5.2 Mycobacterial topoisomerase I 
There is only one type I topoisomerase in mycobacteria.  
Mycobacterium tuberculosis DNA topoisomerase I is validated as a target 
for TB therapy (Nagaraja et al., 2017).  The challenge of the study of M. 
tuberculosis is that it is an infection and slow-growing bacteria.  But M. 
smegmatis growth is faster than M. tuberculosis; it serves as a non-
infection model to study M. tuberculosis DNA topoisomerase I from M. 
smegmatis MC2155 contains 936 residues (MsTOP1), and DNA 
topoisomerase I from M. tuberculosis H37RV contains 934 residues 
(MtTOP1).  Previous studies revealed that MtTOP1 is essential for the cell 
survival of M. tuberculosis (Ahmed et al., 2014). Mycobacterial 
topoisomerase I is essential for maintenance of cellular phenotype, cell 
growth characteristics and gene expression in mycobacteria (Ahmed et 
al., 2014; Ahmed et al., 2015). 
Mycobacterium smegmatis DNA topoisomerase I and 
Mycobacterium tuberculosis DNA topoisomerase I were both reported to 
have the DNA cleavage, religation, binding, relaxation and catenation 
activities (Bhaduri et al., 1998).  The NTD of mycobacterial topoisomerase 
I is sufficient for the DNA binding, DNA cleavage and religation steps, but 
requires CTD for relaxation of negatively supercoiled DNA (Jain and 
Nagaraja, 2006).  Both NTD and CTD of MsTOP1 could bind to ssDNA 
and dsDNA, but NTD of MsTOP1 can bind specific and nonspecific DNA 
(Jain and Nagaraja, 2006).   Mycobacterial topoisomerase I proteins have 
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no Zn2+ binding domains in their CTD (Jain and Nagaraja, 2006).   A 
recent study reported that the CTD of MsTOP1 contains three highly 
conserved stretches of basic amino acids. These basic amino acids are 
involved in DNA binding and promotion of strand passage mechanism 
(Ahmed et al., 2013).  Depletion of these basic amino acids lead to the 
loss of catalytic activity and affect the growth of M. smegmatis.  Besides, 
Dr. Nagaraja’s study revealed that wild-type MsTOP1 and mutant enzyme 
with deletion of stretch 1(KKGKK) could bind two DNA molecules (Ahmed 
et al., 2013).  Dr. Nagaraja revealed that MsTOP1 contained two DNA 
binding sites, one is in NTD and another is in CTD.  A recent study 
showed metal binding amino acids (D108 and E112) in MtTOP1 (Godbole 
et al., 2015). 
 
I.6 Overview of the study 
Type IA topoisomerases are essential in all organisms. 
Mycobacterial topoisomerase I is the important enzyme for mycobacteria.  
It plays important roles in DNA replication, transcription and recombination 
process. It is required in mycobacteria cellular growth, phenotype, gene 
stability and expression.  However, the exact structure and mechanism of 
mycobacterial topoisomerase I remain to be fully elucidated.  The NTD’s 
function is conserved within type IA topoisomerases, but the CTD’s 
sequence and domain organization of mycobacterial topoisomerase I are 
different from other type IA topoisomerases, such as EcTOP I and EcTO 
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III.  Hence, the overall goal of this study is to reveal the structure and 
mechanism of mycobacterial topoisomerase I with X-ray crystallography 
and biochemical catalytic activity analysis.  
The first aim of the current study is to determine the effects of 
deletion of proposed C-terminal subdomains on mycobacterial 
topoisomerase I activity.  The CTD of mycobacterial topoisomerase I could 
be divided into four subdomains and a C-terminal tail.  The catalytic 
activity assays are carried out to study the function of each subdomain at 
the molecular level.  The second aim of the study is to determine the 
crystal structure of deletion mutants, and the catalytic roles of conserved 
amino acid residues in the active site of mycobacteria topoisomerase I.  
Crystal structures of MtTOP1 were obtained.  The crystal structures 
revealed that certain conserved amino acids are required for DNA binding 
or divalent ion interaction.  Conserved amino acids include MtTOP1 E24 
and MsTOP1 E21, were studied.  
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CHAPTER 1: MECHANISM AND FUNCTION OF SUBDOMAINS IN 
MYCOBACTERIAL TOPOISOMERASE I C-TERMINAL DOMAIN 
 
ABSTRACT 
DNA topoisomerase I is an essential enzyme for eukaryotes and 
prokaryotes. Mycobacterial topoisomerase I overcomes the topological 
problems of chromosomes in mycobacteria and maintain the growth of 
mycobacteria.  The NTD of mycobacterial topoisomerase I contain the 
active site for DNA binding, cleavage and religation. The CTD of 
mycobacterial topoisomerase I (Mycobacterium tuberculosis 
topoisomerase I and Mycobacterium smegmatis topoisomerase I) can be 
divided into four subdomains (D5-D8) and a positively charged tail.  Each 
subdomain has a GxxGPY sequence motif.  The current study shows the 
involvement of subdomains in catalysis of different reactions by 
mycobacterial topoisomerase I.  Subdomains D8 and D7 are required for 
maintaining the relaxation activity of mycobacterial topoisomerase I.  
Subdomain D5 in the absence of the other C-terminal subdomains is 
sufficient for the DNA cleavage, religation, catenation and decatenation 
activity. 
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INTRODUCTION  
Tuberculosis (Rosenbaum et al.) is a global  infectious disease. It 
has infected about one-third of the world’s populations. The World Health 
Organization reported 6.3 million new cases of TB in 2016 (WHO, 2017).  
Multidrug-resistance TB (MDR-TB) is a global problem for TB treatment 
(Mishra et al., 2015).  As a top cause of death from the infectious disease, 
more efficient treatment for TB and MDR-TB is an urgent need.  
Tuberculosis is caused by various strains of mycobacteria, usually 
Mycobacterium tuberculosis (M. tuberculosis) (Veatch and Kaushal, 
2017). 
DNA topoisomerases are ubiquitous in both eukaryotes and 
prokaryotes. They are involved in DNA replication, recombination, 
transcription, and repair processes.  They are essential enzymes that 
could regulate DNA topology for optimal growth of eukaryotic and 
prokaryotic organisms (Vos et al., 2011).  There are two types of 
topoisomerases, type I topoisomerase (Topo I) and type II topoisomerases 
(Topo II) (Bush et al., 2015).  Type I DNA topoisomerases cleave and 
rejoin a single strand of DNA. There are three sub-types of type I 
topoisomerases, topoisomerase IA, topoisomerase IB and type IC 
topoisomerase (Chen et al., 2013).  The enzymes of type IA subfamily 
include bacterial DNA topoisomerase I, bacterial DNA topoisomerase III, 
eukaryotic DNA topoisomerase III and reverse gyrase (Tse-Dinh, 1998).  
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Type I topoisomerases can relax supercoiled DNA and type IA 
topoisomerases are classified to relax only negatively supercoiled DNA 
with Mg2+ requirement.  In mycobacteria, there are two types of 
topoisomerases, mycobacterial topoisomerase I and gyrase.  
Mycobacterial topoisomerase I and E. coli topoisomerase I both belong to 
the type IA topoisomerase family.  The bacterial topoisomerase I can bind 
and cleave single-stranded DNA. It also has the ability to unknot/knot or 
decatenate/catenate single-stranded DNA circles or double-stranded DNA 
circles with a nick (Bugreev and Nevinsky, 2010).  The NTD of type IA 
topoisomerase I are conserved, but the CTD can be found with a variety in 
size and sequence (Strzalka et al., 2017; Viard and de la Tour, 2007).  
The CTD of E. coli topoisomerase I contains three tetracysteine Zinc 
ribbon motifs. These Zinc ribbon motifs are specified by Cys-X2-Cys-Gly-
X2-Met-X12-13-Cys-X4-10-Cys sequence (Tse-Dinh and Beran-Steed, 1988), 
and are essential for the relaxation activity of E. coli topoisomerase I.  It 
has been proposed that the Zinc ribbon motifs bind to single-stranded 
DNA and facilitate DNA stand passage (Ahumada and Tse-Dinh, 2002).  
Mycobacterial topoisomerase I is essential for maintenance of the 
phenotype, growth and gene expression in mycobacteria (Ahmed et al., 
2014; Ahmed et al., 2015).  Mycobacterium tuberculosis topoisomerase 1 
(MtTOP1) is validated as a potential target for anti-tuberculosis therapy 
(Ravishankar et al., 2015; Tse-Dinh, 2009).  In MtTOP1, the active site 
Tyr342 is in the NTD (Tan et al., 2016).  The NTD of M. smegmatis 
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topoisomerase I (MsTOP1) is required during the DNA cleavage and 
religation steps (Jain and Nagaraja, 2006).  The CTD of MsTOP1 is 
proposed to be required for interaction with the passing strand of DNA 
(Ahmed et al., 2013).  We hypothesize that mycobacterial topoisomerase I 
C-terminal has repeated motifs distinct from the Zinc ribbon motifs that 
play the important function in catalysis. Deletion mutants (Figure1.1) were 
unstructured to examine the roles of the individual subdomains. To study 
the CTD of mycobacterial topoisomerase I, the CTD was divided into four 
subdomains and a positively charged tail (Figure1.1, Table1.1).  Each 
subdomain contains a GxxGPY sequence motif. Our structure studies 
showed that each subdomain comprises of four β-strands and one C-
terminal α-helix (Figure 1.2) (Tan et al., 2016) 
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Figure 1.1 The subdomain organization of mycobacterial topoisomerase I.  
The CTD mutants of mycobacterial topoisomerase I are constructed with 
deletions of D5, D6, D7 and D8 subdomain. 
 
 
 
 
Figure 1.2 Division of the C-terminal domain of M. tuberculosis 
topoisomerase I in four subdomains and a flexible tail.  The conserved 
residues among the four subdomains are highlighted in red, including the 
GxxGPY sequence motif.  
 
for 1.3 million deaths. MtTOP1 has been actively
investigated as a target for novel TB drugs [6–8] that
are very much needed for the treatment of drug-re-
sistant TB. The structure of MtTOP1 will be essential
for structure-based rational drug discovery efforts.
Our early trials to obtain diffraction-quality crystals of
the full-length MtTOP1 protein were unsuccessful.
Constructs of the MtTOP1 N-terminal region corre-
sponding to the N-terminal domains D1–D4 found in
Escherichia coli topoisomerase I (EcTOP1) crystal
structures did not express well as soluble proteins. In a
recently determined structure of full-length EcTOP1 in
complex with single-stranded DNA (ssDNA) [9] (PDB
ID: 4RUL), theC-terminal regionofEcTOP1comprises
three 4-Cys zinc ribbon domains and two zinc
ribbon-like domains, and a modular ssDNA-binding
modewas observed. This suggests that theC-terminal
region of MtTOP1 may also contain multiple domains
with repeated and conserved sequence motifs even
though the sequences of EcTOP1 and MtTOP1
C-terminal regions are very different with essentially
no homologies. We analyzed the structural aspects of
the C-terminal region of MtTOP1. The recognition of
individual domains in this region helped us redesign
constructs for functional studies and enabled us to
obtain diffraction-quality crystals for structural charac-
terization of MtTOP1. We report here the crystal
structure of MtTOP1-704t with the N-terminal domains
D1–D4 and the C-terminal domain D5 (amino acids
A2–T704) and its functional characterizations.
Results
Analysis of C-terminal domains of MtTOP1
MtTOP1 does not have easily recognizable se-
quence motifs (such as the repeated 4-Cys Zn-binding
motifs present in EcTOP1) that can help divide the
MtTOP1C-terminal region into domains.Nevertheless,
MtTOP1 does bear four GxxGPY sequencemotifs [10]
in its C-terminal region. Based on the locations of
the four GxxGPY repeats, we divided the region into
four repeat domains (Fig. 1). A secondary structure
prediction indicated that each domain comprises three
or four β-strands and one C-terminal α-helix [11]. The
predicted folding of the MtTOP1 C-terminal domains is
different from the zinc ribbon domains or zinc
ribbon-like domains found in EcTOP1 andThermotoga
maritima topoisomerase I [12]. After the fourth or last
C-terminal domain, there is an additional long highly
positively charged tail (~26 amino acids) in MtTOP1.
Besides the basic C-terminal tail, there are two more
stretches of basic amino acids [13]. Based on the
prediction, one is a part of the insertion on the loop
between theβ3andβ4 strandsofD6, and theother one
is a part of the linker between the D7 and D8 domains
(Fig. 1). Deletions of the stretches of basic amino acids
in the C-terminal region of MtTOP1 have been shown
to affect DNA binding and DNA strand passage [13].
The deletions would unlikely make an impact on the
folding of the individual C-terminal domains but may
affect the relative orientations of the C-terminal
domains and the interdomain flexibility.
MtTOP1-704t is oneof the constructs that havebeen
made based on the C-terminal domain prediction
mentioned above. It spans from amino acid A2 to
amino acid T704 and includes the N-terminal domains
and the first predicted C-terminal domain D5 (Fig. 1
and Graphical Abstract). The functional and structural
characterization of MtTOP1-704t is the focus of this
study.
Biochemical activities of MtTOP1-704t
MtTOP1-704t can be expressed readily as a
soluble recombinant protein in E. coli host strain T7
Express Crystal. The protein was purified to N99%
homogeneity and assayed for relaxation of nega-
tively supercoiled plasmid DNA. The results in Fig. 2
showed that, while relaxation activity can be
detected with 6.2 ng (60 fmol) of the full-length
MtTOP1, relaxation activity was not observed with
100 ng (1.3 pmol) of MtTOP1-704t.
Although relaxation activity could not be detected
for MtTOP1-704t, the protein was found to have DNA
cleavage activity similar to that of full-length MtTOP1
(Fig. 3a). The same preferred cleavage site with a
Fig. 1. Division of the C-terminal region of M. tuberculosis topoisomerase I into four domains and a flexible tail. The
conserved residues among the four domains are highlighted in red, including the GxxGPY sequence motif. Besides the
conserved tyrosine residues within the GxxGPY motifs, other possible DNA-binding residues are highlighted in magenta
(for possible π-stacking to the bases of nucleoti es) or blue (for possible π-cation or s lt bridge or hydrogen bond to DNA).
The secondary structures of D5 are indicated above the appropriate sequence of D5. The highly positively charged tail
after D8 is listed b low the align ent, and it is presumably structurally flexible.
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 NTD+D5+D6
+D7+D8+tail 
NTD+D5+D6
+D7+D8 
NTD+D5+D6+D
7 
NTD+D5+D6 NTD+D5 
Mycobacterium 
tuberculosis 
topoisomerase I 
(MtTOP1) 
MtTOP1                          
(2-934) 
MtTOP1-910t        
(2-910) 
MtTOP1-840t         
(2-840) 
MtTOP1-786t     
(2-786) 
MtTOP1-704t     
(2-704) 
Mycobacterium 
smegmatis 
topoisomerase I 
(MsTOP1) 
MsTOP1                        
(1-936) 
MsTOP1-909t           
(2-909) 
MsTOP1-839t         
(1-839) 
MsTOP1-785t    
(1-785) 
MsTOP1-701t    
(1-701) 
Table 1.1 The construction of wild-type and mutant recombinant mycobacterial topoisomerase I clones that 
include the residues shown in the brackets. 
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MATERIALS AND METHOD 
Construction of plasmids and clones 
The M. smegmatis topA gene was cloned from M. smegmatis 
MC2155.  The genomic DNA was purified from M. smegmatis MC2155 with 
Quick-DNA Fungal/Bacterial Kit (Zymo Research).  The M. tuberculosis 
topA gene was cloned from M. tuberculosis H37RV. Mycobacterium 
tuberculosis H37RV genomic DNA was provided by BEI resources.  The 
polymerase chain reaction (PCR) was used to amplify wild-type and 
mutant mycobacterial topoisomerase I coding sequence. The MsTOP1 
plasmid was constructed with the Gibson Assembly method to insert the 
MsTOP1 gene into a pET-His6-Mocr TEV-LIC cloning vector (2O-T). The 
2O-T MtTOP1 plasmid was constructed in our lab (Annamalai et al., 
2009).  NEBbuilder HIFI DNA Assembly method was used to insert coding 
sequence for MsTOP1-909t and MtTOP1-910t into the 2O-T vector. 
MsTOP1-839t, MsTOP1-786t, MsTOP1-701t, MtTOP1-840t, MtTOP1-
786t, MtTOP1-704t were cloned by site directed mutagenesis to substitute 
a stop codon in the 2O-T MsTOP1 and 2O-T MtTOP1 plasmid. The 
primers (from Sigma Genosys) used for cloning are listed in Table 1.2. 
(IBC-16-009-CR02) 
In the construction of 2O-T MsTOP1, the linear 2O-T plasmid was 
amplified using the Q5 High-Fidelity DNA Polymerase (New England 
Biolabs) and 2O-T plasmid as template (35 cycles of 98°C for 30 sec, 
70°C for 30 sec, 72°C for 3.5 min).  M. smegmatis MC2155 genomic DNA 
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was used as the template to amplify MsTOP1 coding gene with Q5 Hot 
Start High-Fidelity DNA Polymerase (35 cycles of 98°C for 30 sec, 72°C 
for 3 min).  After PCR reaction, the PCR products were purified by 
electrophoresis in 1% agarose gel with Tris-acetate-EDTA buffer (TAE, 40 
mM Tris, 20 mM acetic acid, and 1 mM EDTA).  The gels were stained 
with 1 µg/mL concentration ethidium bromide for 1 hour and photographed 
over UV light.  The PCR products were purified from the excised gel slice 
with GeneJET PCR Purification Kit (Thermo Scientific).  Purified PCR 
product MsTOP1 (0.45 pmol ) and 2O-T (0.14 pmol) (the ratio is 3:1) were 
incubated with Gibson Assembly Master Mix (New England Biolabs) at 
50°C for 15min.  Assembled product was transformed into NEB turbo 
competent cells (New England Biolabs).  The transformants were plated 
on LB + 100 µg/ml carbenicillin + 2% glucose plates and incubated at 
37°C overnight.  
In the construction of 2O-T MsTOP1-909t and 2O-T MtTOP1-910t, 
the linear 2O-T plasmid was amplified using the Q5 Hot Start High-Fidelity 
DNA Polymerase (New England Biolabs).  2O-T MsTOP1 and 2O-T 
MtTOP1 plasmids were used as template for 2O-T MsTOP1-909t and 2O-
T MtTOP1-910t.  The PCR reaction to amplify 2O-T MsTOP1-909t used 
Q5 Hot Start High-Fidelity DNA Polymerase for 35 cycles of 98°C for 30 
sec, 71°C for 30 sec, 72°C for 2.5 min.  The PCR reaction to amplify 2O-T 
MtTOP1-910t used Q5 Hot Start High-Fidelity DNA Polymerase to react 
for 35 cycles of 98°C for 30 sec, 71°C for 30 sec, 72°C for 2 min.  After 
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PCR reaction, the PCR products were purified by electrophoresis in 1% 
agarose gel with TAE buffer. The gels were stained with 1 µg/mL 
concentration ethidium bromide for 1 hour and photographed over UV 
light.  The PCR products were purified from the excised gel slice with 
GeneJET PCR Purification Kit.  Purified PCR product MsTOP1 (0.014 
pmol) and 2O-T (0.14 pmol) (the ratio is about 2:1) were incubated with 
NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs) at 50°C 
for 15 min.  Assembled product was transformed into NEB turbo 
competent cells.  The transformants were plated in the LB + 100 µg/ml 
carbenicillin + 2% glucose plates and incubated at 37°C overnight.  
The materials and protocol for site-detected mutagenesis are 
described in Table 1.3.  After PCR mutagenesis reactions, the PCR 
products were purified by electrophoresis in 1% agarose gel with TAE 
buffer.  The template plasmids were digested by treatment with Dpn1 
restriction enzyme (New England Biolabs) or KLD mix (kinase, ligase, 
DpnI; New England Biolabs).  NEB turbo competent cells and NEB 5α 
competent cells (New England Biolabs) were used for the transformation 
of mutant plasmids. The transformants were plated on the LB + 100 µg/ml 
carbenicillin + 2% glucose plates.  
Wild-type and mutant plasmids were purified by GeneJET Plasmid 
Miniprep Kit (Thermo Scientific).  Nucleotide sequencing (Genewiz and 
Eurofins genomics) was used to verify the sequence of the complete 
coding region of plasmids. 
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Primer name Primer sequence (5’-3’) 
MsTOP1 forward 
GGGATCGAGGAAAACCTGTACTTCCAAATGGCTGGCG
GCGACCG 
MsTOP1 reverse 
GCGGATCCGTTATCCACTTCCAATATTGTTCGGCGGA
AACCTAGGCCTTCTT 
MsTOP1-909t 
forward 
GGGATCGAGGAAAACCTGTACTTCCAAATGGCTGGCG
GCGACCG 
MsTOP1-909t 
reverse GAGTCCGGACACCTTGGAAGTACAGGTTTTCC 
MsTOP1-839t 
forward CGGCCACGGCGTTTCTACTCGGCGTAGATCTT 
MsTOP1-839t 
reverse AAGATCTACGCCGAGTAGAAACGCCGTGGCCG 
MsTOP1-785t 
forward GCCCACGACGCGCTACAGCGACAGCAGC 
MsTOP1-785t 
reverse GCTGCTGTCGCTGTAGCGCGTCGTGGGC 
MsTOP1-701t 
forward GCGTCCCTCTTGCTATGTGGCGAAGAGCTTTTCGG 
MsTOP1-701t 
reverse CCGAAAAGCTCTTCGCCACATAGCAAGAGGGACGC 
MtTOP1-910t 
forward 
GATCGAGGAAAACCTGTACTTCCAATTGGCTGACCCG
AAAACGAAGGG 
MtTOP1-910t 
reverse 
GCGGATCCGTTATCCACTTCCAATATTGCTAGGCTCG
GCGATCGGCCAA 
MtTOP1-840t 
forward CCGGCCACGACGTTTCTACTCTGCGTAGATCTTC 
MtTOP1-840t 
reverse GAAGATCTACGCAGAGTAGAAACGTCGTGGCCGG 
MtTOP1-786t 
forward GCTGTCACTGTAGCGCGTGGTCG 
MtTOP1-786t 
reverse AGCCTCAGCGCGTCTTCG 
MtTOP1-704t 
forward 
GTCCCTGTTGCTATGTGGCAAAGAGCTCTTCGGC 
MtTOP1-704t 
reverse 
GCCGAAGAGCTCTTTGCCACATAGCAACAGGGAC 
2O-T forward TTGGAAGTACAGGTTTTCCTCGATCCC 
2O-T reverse CAATATTGGAAGTGGATAACGGATCCGC 
Table 1.2 Primer sequences used for clone construction. 
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Plasmid 
name 
DNA polymerase 
used for cloning 
Methods and Protocol  Digestion 
enzyme 
Transformation 
competent cells 
2O-T 
MsTOP1-839t  
Phusion Hot Start II 
High-Fidelity DNA 
Polymerase (Thermo 
Scientific) 
QuickChange site-directed 
mutagenesis (30 cycles of 95°C 
for 30 sec, 70°C for 30 sec, 72°C 
for 4.5 min) 
Dpn1 NEB turbo 
2O-T 
MsTOP1-785t  
Phusion Hot Start II 
High-Fidelity DNA 
Polymerase (Thermo 
Scientific) 
QuickChange site-directed 
mutagenesis (30 cycles of 95°C 
for 30 sec, 70°C for 30 sec, 72°C 
for 4.5 min) 
Dpn1 NEB turbo 
2O-T 
MsTOP1-701t  
Phusion Hot Start II 
High-Fidelity DNA 
Polymerase (Thermo 
Scientific) 
QuickChange site-directed 
mutagenesis (30 cycles of 95°C 
for 30 sec, 70°C for 30 sec, 72°C 
for 4.5 min) 
Dpn1 NEB turbo 
2O-T 
MtTOP1-840t 
Phusion Hot Start II 
High-Fidelity DNA 
Polymerase (Thermo 
Scientific) 
QuickChange site-directed 
mutagenesis (30 cycles of 95°C 
for 30 sec, 70°C for 30 sec, 72°C 
for 4.5min) 
Dpn1 NEB turbo 
2O-T 
MtTOP1-786t 
Q5 Hot Start High-
Fidelity Master Mix 
(New England 
Biolabs) 
Q5 site-directed mutagenesis 
(25 cycles of 95°C for 30 sec, 
65°C for 30 sec, 72°C for 4.5 min) 
 
KLD mix NEB 5α 
2O-T 
MtTOP1-704t 
Phusion Hot Start II 
High-Fidelity DNA 
Polymerase (Thermo 
Scientific) 
QuickChange site-directed 
mutagenesis (30 cycles of 95°C 
for 30 sec, 70°C for 30 sec, 72°C 
for 4.5 min) 
Dpn1 NEB turbo 
Table 1.3 Methods and materials used for site directed mutagenesis of mycobacterial topoisomerase I
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Protein expression and purification 
Wild-type MsTOP1 and its mutant proteins were overexpressed in E. coli 
BL21 star (DE3) strain (Invitrogen).  Wild-type MtTOP1 and its mutant proteins 
were overexpressed in E. coli T7 Express crystal strain (New England Biolabs).   
The cells were grown at 30°C overnight. Overnight cell cultures diluted 1:100 
were incubated in LB medium with 100 µg/ml carbenicillin at 30°C to exponential 
phase (OD600=0.4).  1 mM IPTG was added to BL21 star (DE3) cell culture.  0.4 
mM IPTG was added to T7 express crystal cell culture.  Induced cell culture was 
grown at 22°C overnight.  Cell cultures were centrifuged at 4500 rpm at 4°C for 
30 min.  Cell pellets were resuspended in lysis buffer (50 mM sodium phosphate, 
0.3 M NaCl, 10 mM imidazole, and 1 mg/ml lysozyme, pH8.0).  The resuspended 
cell mixture was left on ice for 1 hr.  Four cycles of freeze–thawing were used to 
lyse cell.  The cell lysate was centrifuged at 32000 rpm at 4°C for 2 hr.  The 
soluble cell lysate were collected and mixed with Ni-Sepharose 6 Fast Flow 
beads (GE Healthcare) at 4°C for 1 hr.  The beads were packed into a column 
and the AKTA purifier 100 (GE healthcare Life Sciences) was used for 
purification.  About 350 ml of wash buffer (50 mM sodium phosphate, 0.3 M 
NaCl, 20 mM imidazole, pH 8.0) were used to wash column after sample loading.  
Recombinant proteins were eluted with elution buffer (50 mM sodium phosphate, 
0.3 M NaCl, 400 mM imidazole, pH 8.0).  The eluted fractions were analyzed with 
10% SDS-PAGE gel and eluted fractions with recombinant proteins were 
dialyzed against buffer A (20 mM potassium phosphate, 1 mM EDTA pH 8.0, 
10% glycerol) + 0.1 M KCl. TEV protease (tobacco etch virus protease) (Kapust 
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et al., 2002) was added to the purified protein after dialysis at the ratio of 1:40 
(TEV protease: purified protein).  The His-tagged TEV protease was purified in 
our lab. The recombinant protein with His-Mocr tag was digested at 20°C for 6 hr 
followed by incubation at 4°C overnight in reaction buffer (50 mM Tris-HCl, 0.5 
mM EDTA and 1 mM DTT, pH 8.0).  Ni-Sepharose 6 Fast Flow resin (GE 
Healthcare Life Sciences) was used to remove cleaved N-terminal His6-Mocr tag 
and His-tagged TEV protease.  The recombinant proteins were eluted with wash 
buffer (20 mM Tris-HCl, 0.3 mM KCl, pH 8.0) and concentrated with Ultra 
Centrifugal Filters (EMD Millipore) to ~10 ml.  Recombinant proteins were then 
loaded onto size exclusion chromatography column HiPrep™ 26/60 
Sephacryl® S-200 (GE Healthcare Life Sciences) to remove nuclease and 
proteins co-eluted in previous steps. Recombinant proteins were eluted with 
column buffer (20 mM Tris-HCl, 0.3 M KCl, pH 8.0) and dialyzed against storage 
buffer (0.1 M potassium phosphate, 0.2 mM EDTA pH 8.0, 50% glycerol). The 
final step is to measure the protein concentrations with the Bio-Rad Bradford 
protein assay using bovine serum albumin (BSA, Bio-Rad) as standard. 
Complementation of topA temperature sensitive mutation in E. coli AS17 
strain 
Wild-type and mutant mycobacterial topoisomerase I clones in the 2O-T 
vector were electro-transformed into E. coli AS17 (F- topA17(am) pLL1(Tet 
supD43,74)) strain.  The AS17 transformants were grown at 30°C overnight, in 
LB medium with 100 µg/ml carbenicillin.  The OD600 of overnight cultures were 
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checked and adjusted to OD600=1 with LB medium (100 µg/ml carbenicillin).  The 
adjusted cell culture was serially diluted with LB medium (100 µg/ml carbenicillin) 
and 5 µl each dilution was spotted on LB agar plate with 100 µg/ml carbenicillin.  
The plates in duplicates were incubated at 30°C and 42°C for 2 days. 
 
Relaxation assay 
Wild-type and mutant mycobacterial topoisomerase I proteins were serially 
diluted.  Diluted proteins were incubated with 250 ng negatively supercoiled 
plasmid pBAD/thio (purified by CsCl density gradient centrifugation) in the 
volume of 20 µL with 10 mM Tris–HCl (pH 8.0), 100 mM NaCl, 0.1 mg/ml gelatin, 
and 5 mM MgCl2 at 37°C for 30 min.   The reactions were terminated by addition 
of 4 µL of stop buffer (50 mM EDTA, 50% glycerol and 0.5% (v/v) bromophenol 
blue).  The DNA was then electrophoresed in a 1% agarose gel with TAE buffer 
(40 mM Tris-acetate, pH 8.0, 2 mM EDTA).  The gels were stained with 1 µg/mL 
concentration ethidium bromide for 1 hr and photographed over UV light.  
In the relaxation rate assay of wild-type and mutant proteins without C-
terminal tail, 30 ng wild-type MtTOP1, wild-type MsTOP1, MtTOP1-910t and 
MsTOP1-909t was incubated with 250 ng negatively supercoiled plasmid 
pBAD/thio in 20 µl of 10 mM Tris–HCl (pH 8.0), 100 mM NaCl, 0.1 mg/ml gelatin, 
and 5 mM MgCl2 at 37°C for 1, 2, 3, 6, 9, 12, 15, 30 min.  The reactions were 
terminated with 4 µL of stop buffer and analyzed by electrophoresis in 0.8% 
agarose gel with TAE buffer.  The gels were stained with 1 µg/mL ethidium 
bromide for 1 hour and photographed over UV light.  
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In the relaxation assay of wild-type MsTOP1 and MsTOP1-839t, 100 ng 
MsTOP1, 100 ng MsTOP1-839t and 400 ng MsTOP1-839t were incubated with 
250 ng negatively supercoiled plasmid pBAD/thio in 20 µl of 10 mM Tris–HCl 
(pH 8.0), 50 mM NaCl, 0.1 mg/ml gelatin, and 5 mM MgCl2 at 37°C for different 
times, the reactions were terminated with 4 µl of stop buffer and analyzed by 
electrophoresis in 1% agarose gel with TAE buffer. The gels were stained with 1 
µg/mL concentration ethidium bromide for 1 hour and photographed over UV 
light.  
Electrophoretic mobility shift assay (EMSA) 
The oligonucleotide substrates STS32 and MT3 (Table 1.4) were labeled 
with γ-32P-ATP at the 5’ end by T4 polynucleotide kinase (New England 
BioLabs).  The labeling reactions were carried out at 37°C for 30 min and 
terminated at 75°C for 15min.   γ-32P labeled oligonucleotide substrates were 
purified after the labeling reaction using a Sephadex G-50 spin column (STS32) 
or Sephadex G-25 column (MT3) (GE Healthcare).  Purified substrates were 
eluted in 10 mM Tris-HCl, pH 8.0.  The electrophoretic mobility shift assay was 
carried out in 10 µl of 20 mM Tris-HCl (pH8.0), 100 µg/ml BSA, 18% glycerol, 0.5 
mM EDTA.  In the STS32 mobility shift assay, 1-4 pmol wild-type MtTOP1 and 
MsTOP1, or mutant proteins were incubated with 5 pmol STS32 at 37°C for 5 
min.  In the MT3 electrophoretic mobility shift assay, 1-10 pmol wild-type MtTOP1 
and MsTOP1, mutant proteins MtTOP1-704t and MsTOP1-701t were incubated 
with 2.5 pmol MT3 at 37°C for 5 min.  The reactions were then placed on ice for 5 
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min.  The non-covalent protein-DNA complex and free substrate were separated 
by electrophoresis in 8% polyacrylamide gel with 0.5×TBE (45 mM Tris-HCl, 45 
mM Borate, 1 mM EDTA, pH 8.3) buffer at 6 V/cm for 4.5 hours. The gels were 
vacuum dried at 80°C for 2 hours.  The dried gel was analyzed by Phosphor-
lmager. 
 
Cleavage assay  
The oligonucleotide substrates in Table 1.4 were labeled with γ-32P-ATP 
at the 5’ end.  1 pmol of wild-type MtTOP1 and MtTOP1-704t were incubated 
with 0.5 pmol 32P-labeled oligonucleotide substrates STS32, MT2-13, MT2-14, 
MT3, MT3-N13, MT3-C13 in 5 µl of 10 mM Tris–HCl (pH 8.0) at 37°C for 30 min.  
Wild-type MtTOP1, wild-type MsTOP1 and mutant proteins were serially diluted 
to 2 pmol/µl, 1 pmol/µl, 0.5 pmol/µl, 0.25 pmol/µl, 0.125 pmol/µl, and 0.63 
pmol/µl. 0.5 pmol oligonucleotide substrates were incubated with serially diluted 
proteins in 5 µl of 10 mM Tris–HCl (pH 8.0) at 37°C for 30 min.  The equal 
volume of loading buffer (79% formamide, 0.2 M NaOH, 0.04% bromophenol 
blue) was added to terminate the cleavage reactions.  All the reactions were then 
heated at 95 °C for 5 min.  The long oligo (STS32 and MT2) cleavage products 
were electrophoresed in 15% sequencing gel.  The short oligo (MT3, MT2-13 and 
so on) cleavage products were electrophoresed in 20% sequencing gel.  The 
TBE buffer (89 mM Tris-Cl, 89 mM Borate, 2 mM EDTA pH 8.3) was used as 
running buffer.  Gels were analyzed by Phosphor-lmager. 
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In the cleavage assay using substrate MT3 with Mg2+, the oligonucleotide 
substrate MT3 was labeled with γ-32P-ATP at the 5’ end.  1 pmol wild-type 
MtTOP1, MtTOP1-840t, MtTOP1-786t and MtTOP1-704t were incubated with 0.5 
pmol oligonucleotide substrate MT3 in 5 µl of 10 mM Tris–HCl (pH 8.0) at 37°C 
for 15 min.  1 M NaCl and 5 mM MgCl2 were added into the cleavage reaction for 
15 min further incubation at 37°C.  Another reaction condition is to add 2 mM 
MgCl2 into the cleavage reaction for 5 min further incubation at 37 °C.  The 
reactions were terminated with equal volume of loading buffer (79% formamide, 
0.2 M NaOH, 0.04% bromophenol blue) and heated at 95 °C for 5 min.  The 
reaction products were analyzed by electrophoresis in 15% sequencing gel.  The 
TBE buffer was used as running buffer.  Gels were analyzed by Phosphor-
lmager. 
 
 
Oligo name Oligo sequence (5’-3’) 
STS32 5′-CAGTGAGCGAGCTTCCGCêTTGACATCCCAATA-3′ 
MT2 5’-CAGTGAGCGAGCTTCCGCêTTGACTT-3’ 
MT2-14 5’-CTTCCGCêTTGACTT-3’ 
MTS2-13 5’-TTCCGCêTTGACTT-3’ 
MT3 5’-CTTCCGCêTTGACAT-3’ 
MT3-C13 5’-TTCCGCêTTGACAT-3’ 
MT3-N13 5’-CTTCCGCêTTGACA-3’ 
Table 1.4 Oligos used in cleavage assay. Arrows indicate the cleavage site. 
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Religation assay 
The oligonucleotide substrate STS32 were labeled with γ-32P-ATP at the 
5’ end.  In the religation assay, 1 pmol wild-type and mutant proteins were 
incubated with 0.5 pmol oligonucleotide substrate STS32 in 5 µl of 10 mM Tris–
HCl (pH 8.0) at 37°C for 15 min. 1 M NaCl, 5 mM or 10 mM MgCl2 were added 
into the cleavage reaction respectively for 15 min further incubation at 37°C.  The 
reactions were terminated with equal volume of loading buffer (79% formamide, 
0.2 M NaOH, 0.04% bromophenol blue) and heated at 95°C for 5 min.  The 
reaction products were analyzed by electrophoresis in 15% sequencing gel. The 
TBE buffer was used as running buffer.  Gels were analyzed by Phosphor-
lmager. 
Catenation assay 
Catenation of M13mp18 ssDNA circles was assayed with a protocol 
similar to previously described conditions (Bhaduri et al., 1998).  Wild-type 
MsTOP1, Wild-type MtTOP1, MtTOP1-704t was diluted into 0.5 pmol/µl, 0.25 
pmol/µl, 0.125 pmol/µl.  The reaction volume of 20 µl contained 20 mM Tris–HCl 
(pH 8.0), 20 mM KCl, 2 mM MgCl2, 0.05 mg/ml BSA, 10 mM spermidine, 30% 
glycerol, and 0.5 µg of M13mp18 ssDNA (from Bayou Biolabs).  After incubation 
with the indicated amount of topoisomerase protein for 1 hr at 52°C, the reactions 
were terminated with the addition of 1% SDS, 5 mM EDTA, and 12 µg of 
proteinase K (New England Biolabs) and were left at 37°C for 1 hr before 
electrophoresis in 0.8% agarose gel.  The TAE buffer was used as running 
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buffer.  The gels were stained with 1 µg/mL concentration ethidium bromide for 1 
hr and photographed over UV light.  
Decatenation assay 
Decatenation of kinetoplast DNA (kDNA) was carried out in the reaction 
volume of 20 µl containing 50 mM Tris–HCl (pH 8.0), 120 mM KCl, 10 mM MgCl2, 
30 mg/ml BSA, 0.5 mM DTT, 30% glycerol, and 150 ng kDNA (from Topogen).  
MtTOP1 and MtTOP1-704t was diluted to 6 pmol/µl, 3 pmol/µl and 1.5 pmol/µl.  1 
µl diluted topoisomerase protein was added to decatenation reaction and 
incubated at 45°C for 1 h.  To test the stability of kDNA in 45°C, kDNA was 
incubated without enzyme at 45°C for 1 hr.  The human topoisomerase IIα was 
used as the positive control for decatenaton activity, The human TOPIIα 
decatenation reaction was carried in 50 mM Tris–HCl (pH 8.0), 120 mM KCl, 10 
mM MgCl2, 3 mM ATP, 30 mg/ml BSA, 0.5 mM DTT, 30% glycerol, and 150 ng 
kDNA (from Topogen).  Reactions were terminated with the addition of 4 µl of 5% 
sarkosyl, 0.025% bromophenol and 50% glycerol before electrophoresis in 1% 
agarose gel. TAE buffer containing 0.5 µg/ml ethidium bromide was used as 
running buffer.  The gels photographed over UV light.  
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RESULTS 
Complementation of topA temperature sensitive mutation in E. coli AS17 by 
recombinant mycobacterial topoisomerase I  
Previous studies showed that E. coli AS17 with the temperature sensitive 
mutation in topoisomerase I gene (topAts) complemented by recombinant 
MtTOP1 could grow at the non-permissive temperatures of 37°C and 42°C 
(Narula et al., 2010).  In the current study, plasmids with mutant MtTOP1 and 
MsTOP1 genes in the 2O-T vector were transformed into E. coli AS17 strain. 
Escherichia coli AS17 strain complemented with 2O-T vector was used as a 
negative control. Escherichia coli AS17 strain complemented with plasmids 2OT-
MtTOP1 and 2OT-MsTOP1 were used as positive control.  As the results showed 
in Figure 1.3, E. coli AS17 with vector could not grow at 42°C.  Wild-type 
MtTOP1 and MsTOP1 complemented the topAts mutation in the chromosome of 
E. coli AS17 and they are sufficient for the growth of E. coli AS17.  Strains 
transformed with mutant plasmids, AS17/2OT MtTOP1-910t, AS17/2OT 
MtTOP1-840t, AS17/2OT MsTOP1-909t, and AS17/2OT MsTOP1-839t also grew 
at 42°C.  Mutant strains AS17/2OT MtTOP1-786t, AS17/2OT MtTOP1-704t, 
AS17/2OT MsTOP1-839t, and AS17/2OT MsTOP1-701t had no growth or little 
growth at 42°C.  These data showed that NTD combined with C-terminal 
subdomains D5 and D6 could not support the growth of E. coli.  The addition of 
subdomain D7 is minimally require for in vivo viability.  
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Figure 1.3 Growth of E. coli AS17 complemented by recombinant mycobacterial 
topoisomerase I at 30°C and 42°C in LB agar plates. 
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Relaxation assay of mycobacterial topoisomerase I with negatively 
supercoiled DNA 
Previous studies showed that MsTOP1 with only NTD (D1-D4) or CTD 
(D5-D8+basic tail) lost the relaxation activity (Jain and Nagaraja, 2006).  The 
truncated proteins of mycobacterial topoisomerase I that retained individual 
subdomains of the CTD may maintain partial relaxation activity.  In the agarose 
gel electrophoresis results, 100 ng wild-type MsTOP1 and wild-type MtTOP1 fully 
relaxed the 250 ng negatively supercoiled DNA substrate (Figure 1.4, Figure 
1.5).  In contrast, 200 ng truncated enzyme MsTOP1-701t and MtTOP1-704t that 
retained D1-D5 did not show any relaxation activity (Figure 1.4A, Figure1.5A).  In 
Figure 1.4B and Figure 1.5B, 100 ng truncated enzyme MsTOP1-785t and 
MsTOP1 786t with D1-D6 did not show any difference from negative control. In 
Figure 1.4C and Figure 1.5C, 200 ng MsTOP1-839t and MtTOP1-840t showed 
partial weak relaxation activity.  Compared to the wild-type mycobacterial 
topoisomerase I, the relaxation activity of MtTOP1-840t and MsTOP1-839t was 
reduced about 16-fold.  Mutant proteins MtTOP1-910t and MsTOP1-909t are 
more active than other truncated enzymes in relaxation assays (Figure 1.4D, 
Figure1.5D).  Compared with products from each reaction of wild-type MtTOP1 
and MsTOP1, the relaxation activity of MtTOP1-910t and MsTOP1-909t 
decreased 2- to 4-fold.  This data shows that truncation mutants with C-terminal 
subdomains D1-D7 retain partial relaxation activity, and it is sufficient for 
supporting the viability of E. coli in vivo when present in high copy number 
plasmid 2O-T.  Subdomain D5 and D6 subdomains combined with NTD could not 
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maintain the relaxation activity of mycobacterial topoisomerase I.  Subdomain D7 
needs to be present for the relaxation of negatively supercoiled DNA.  Serial 
dilutions of MtTOP1-910t and MsTOP1-909t showed that the truncated mutations 
with D1-D8 that were miss the basic tail at the C-terminus had a slight reduction 
in relaxation activity when compared to wild-type. 
Mutant proteins MtTOP1-909t and MsTOP1-910t were incubated with 250 
ng negatively supercoiled DNA for 1, 2, 3, 6, 9, 15, 30, 15 and 60 min and 
compared with 30 ng wild-type MtTOP1 and MsTOP1 incubated at the same 
conditions and times (Figure 1.6).  At each time point, wild-type MtTOP1 and 
MsTOP1 are more active than MtTOP1-910t and MsTOP1-909t.  Mutant proteins 
MtTOP1-910t and MsTOP1-909t have reduced relaxation catalytic rate. The final 
products are more fully relaxed for the wild-type enzymes.  The C-terminal tail 
that is absent in MtTOP1-910t and MsTOP1-909t enhanced the relaxation 
activity and processivity of mycobacterial topoisomerase I.  
Removed of negative supercoils by 30 ng of wild-type and mutant 
mycobacterial topoisomerase I began slow starting from 9-15 min, as the partially 
relaxed DNA has less single-stranded DNA region for binding to the enzyme.  In 
Figure 1.7, 100 and 400 ng MsTOP1-839t was incubated with 250 ng negatively 
supercoiled DNA at 37°C up to 180 min.  MsTOP1-839t exhibited only partial 
relaxation activity even at 180 min and a slow catalytic rate.  This result showed 
that while the presence of D5-D7 can allow relaxation of negatively supercoiled 
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DNA by mycobacterial topoisomerase I, subdomain D8 played an important role 
in the catalysis of the relaxation reaction. 
 
 
 
 
Figure 1.4 Relaxation assays of serially diluted wild-type and mutant MsTOP1 with 
negatively supercoiled pBAD/Thio DNA.  (A) Relaxation assay of wild-type MsTOP1 
and MsTOP1-701t.  (B) Relaxation assay of wild-type MsTOP1 and MsTOP1-785t.  (C) 
Relaxation assay of wild-type MsTOP1 and MsTOP1-839t.  (D) Relaxation assay of wild-
type MsTOP1 with MsTOP1-909t.   No, no enzyme added.
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Figure 1.5 Relaxation assays of serially diluted wild-type and mutant 
MtTOP1 with negatively supercoiled pBAD/Thio DNA.  (A) Relaxation assay 
of wild-type MtTOP1 with MtTOP1-704t.  (B) Relaxation assay of wild-type 
MtTOP1 and MtTOP1-786t.  (C) Relaxation assay of wild-type MtTOP1 and 
MtTOP1-840t.  (D) Relaxation assay of wild-type MtTOP1 and  MtTOP1-910t. 
No, no enzyme added. 
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Figure 1.6 Relaxation time course for mycobacterial topoisomerase I with 
negatively supercoiled pBAD/Thio DNA.  (A) Assays of 30 ng wild-type MtTOP1 and 
MtTOP1-910t.  (B) Assays of 30 ng wild-type MsTOP1 and 30 ng MsTOP1-909t. No, no 
enzyme added. 
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Figure 1.7 Relaxation time course for wild-type MsTOP1 and MsTOP1-839t with 
negatively supercoiled pBAD/Thio DNA.  (A) 100 ng MsTOP1 and 100 ng MsTOP1-
839t were incubated at 37°C for different times (5-60 min).  (B) 400 ng MsTOP1 was 
incubated at 37°C for different times for 30, 60, 120, 150, 180 min. 
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Mycobacterial topoisomerase I truncated mutant proteins with C-terminal 
subdomain D5 only have reduced binding to oligonucleotide STS32 and 
MT3 
In an earlier study, the NTD and CTD of mycobacterial topoisomerase I 
were found to each bind to DNA (Jain and Nagaraja, 2006).  In this study, the 
EMSA of oligonucleotide STS32 and MT3 were used to study the DNA binding 
activity of wild-type and mutant mycobacterial topoisomerase (Figure 1.8, Figure 
1.9).  In the DNA binding assay of STS32, MtTOP1-786t, MtTOP1-704t, 
MsTOP1-785t and MsTOP1-701t showed less binding activity than wild-type and 
other mutant mycobacterial topoisomerase I (Figure 1.8).  Deletion mutation 
proteins MsTOP1-701t and MtTOP1-704t that with NTD and C-terminal 
subdomain D5 have significantly reduced DNA binding activity when compared to 
wild-type mycobacterial topoisomerase I with oligonucleotide STS32.  Wild-type 
MtTOP1 and MsTOP1 also have significantly higher binding activity than 
MtTOP1-704t and MsTOP1-701t with oligonucleotide MT3 (Figure 1.9).  These 
results show that truncated mutant proteins with NTD and C-terminal subdomain 
D5 only have significantly reduced binding to short ssDNA when compared to 
wild-type mycobacterial topoisomerase I.  The C-terminal subdomains likely 
contribute significantly to binding of one of the unwound DNA strand during 
relaxation of negatively supercoiled DNA by mycobacterial topoisomerase I. 
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Figure 1.8 Electrophoretic mobility shift assay for formation of non-covalent 
complex between labeled STS32 oligonucleotide and mycobacterial 
topoisomerase I.  (A) EMSA assay of wild-type MtTOP1 and truncate mutant MtTOP1.  
(B) EMSA assay of wild-type MsTOP1 and truncate mutant MsTOP1.
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Figure 1.9 Electrophoretic mobility shift assay of MtTOP1, MtTOP1-704t, MsTOP1 and MsTOP1-701t with 
labeled MT3 oligonucleotide. 
	 58	
Cleavage activity of mycobacterial topoisomerase I with 32 nucleotide long 
STS32 and 25 nucleotide long MT2 substrate 
We used serially diluted protein to test the cleavage activity of wild-type 
and mutant mycobacterial topoisomerase I with 5’-labeled oligonucleotide STS32 
and MT2.  Oligonucleotide STS32 contains 32 nucleotides, and MT2 contains 25 
nucleotides.  The results of wild-type MtTOP1, MtTOP1-910t, MtTOP1-840t, 
MtTOP1-786t and MtTOP1-704t cleavage activity assay with STS32 substrate 
show that all the truncated mutant M. tuberculosis topoisomerase I can cleave 
this substrate (Figure 1.10). The cleavage activity assay results of wild-type 
MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and MsTOP1-701t with 
oligonucleotide STS32 also show that all the truncated mutant M. smegmatis 
topoisomerase I have cleavage activity with oligonucleotide STS32 (Figure 1.11). 
The cleavage activity results in Figure 1.12 show that wild-type MsTOP1, 
MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and MsTOP1-701t performed DNA 
cleavage on substrate MT2. Figure 1.13 showed that MtTOP1-704t formed a 
higher level of cleavage product than wild-type MtTOP1 with MT2 substrate. 
Similar results were observed between MsTOP1 and MsTOP1-701t (Figure 
1.12).  The deletion of C-terminal subdomains D6-D8 of mycobacterial 
topoisomerase I did not lead to the loss of the cleavage activity.  A previous 
study has concluded that the NTD of MsTOP1 forming at residues 616 can 
cleave DNA (Jain and Nagaraja, 2006).  These studies show that active site of 
mycobacterial topoisomerase I in the NTD can carry out DNA cleavage in the 
absence of most of the CTD.  The results in Figure 1.13 suggest that 
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subdomains D6-D8 may compete with the active site in NTD for binding to the 25 
nucleotides long MT2 substrate, so that more cleavage product is formed from 
the NTD+D5 form of mycobacterial topoisomerase I with the rest of the CTD not 
present.  As protein/oligonucleotide ratio increases, more cleavage product is 
formed from MtTOP1-704t, while cleavage by wild-type becomes suppressed 
because the CTD subdomains may have higher affinity for the MT2 substrate 
than the NTD active site.   The longer length STS substrate may be able to 
interact simultaneously with both the NTD and CTD.  This is further investigated 
with shorter oligonucleotide substrates. 
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Figure 1.10 Cleavage activity assay wild-type MtTOP1, MtTOP1-910t, MtTOP1-840t, MtTOP1-786t and MtTOP1-
704t with STS32 substrate. 
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Figure 1.11 Cleavage activity assay of wild-type MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and 
MsTOP1-701t with STS32 substrate. 
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Figure 1.12 Cleavage activity assay of wild-type MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and 
MsTOP1-701t with MT2 substrate.
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Figure 1.13 Cleavage of MT2 substrate by MtTOP1-704t is more robust than wild-
type MtTOP1.  (A) Assay of MT2 substrate cleavage by serially diluted MtTOP1-704t 
and MtTOP1 cleavage assay with MT2.  (B) Analysis of percentage cleavage product 
analysis. The average deviation from two experiments is shown. 
 
Cleavage assay of mycobacterial topoisomerase I with short 
oligonucleotides 
Short oligonucleotides (Figure 1.14) MT2-14, MT2-13, MT3-N13 and MT3 
contain 13-14 nucleotides. wild-type MtTOP1 at 1 pmol cleavage assay reaction 
did not show any cleavage activity with these short oligos.  However, high 
cleavage activity was observed with 1 pmol MtTOP1-704t and these short oligos. 
Oligonucleotide MT3 (14 nucleotides) is shorter than the 32-nucleotide-long 
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STS32 and 25-nucleotide-long MT2.  When MT3 was titrated with 0.25-2 pmol of 
MtTOP1 and MsTOP1, cleavage activity of substrate MT3 (0.5 pmol) was not 
observed. However, MtTOP1 and MsTOP1 at lower stoichiometry (0.063 and 
0.125 pmol) produced cleavage product from MT3 (Figure 1.15, Figure 1.16).  In 
contrast mutant proteins with deletions in CTD produced cleavage product from 
MT3 at both high and low stoichiometry of enzymes (Figure 1.15, Figure 1.16).  
The DNA binding assay (Figure 1.9) showed that MsTOP1 and MtTOP1 
bind MT3 at higher protein: DNA stoichiometry even when DNA cleavage was 
not observed (Figure 1.15).  These data suggest that the short oligonucleotide 
MT3 has higher affinity for the CTD than the NTD. When the CTD of 
mycobacterial topoisomerase I was fully occupied, additional short 
oligonucleotide will then bind to the NTD active site for DNA cleavage to occur.  
This result shows that the CTD in mycobacterial topoisomerase I is responsible 
for recognition of negatively supercoiled duplex DNA by interacting with one 
strand of the unwound DNA and directing the complementary strand to the NTD 
active site for DNA cleavage. 
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Figure 1.14, Cleavage of short 13-14 base long oligo by MtTOP1-704t but not wild-type MtTOP1.  Wild-type 
MtTOP1 and MtTOP1-704t were incubated with STS32, MT2-14, MTS2-13, MT3, MT3-N13, MT3-C13 at 37°C for 30 
min.
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Figure 1.15 Cleavage activity assay of wild-type MsTOP1, MsTOP1-909t, MsTOP1-839t, MsTOP1-785t and 
MsTOP1-701t with MT3 oligonucleotide substrate. 
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Figure 1.16 Cleavage activity assay of wild-type MtTOP1, MtTOP1-840t, MtTOP1-786t and MtTOP1-704t with 
MT3 oligonucleotide substrate.
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Cleavage oligonucleotide MT3 in the presence of Mg (II) 
It is observed that 1 pmol wild-type MtTOP1 was not able to cleave short 
oligonucleotides in 10 mM Tris-HCl at 37°C.  However, in the cleavage activity 
assay at the presence of 2 mM Mg2+ at 37°C, 1 pmol wild-type MtTOP1 is 
observed to cleave the short oligonucleotide MT3 (Figure 1.17).  In the cleavage 
reaction with Mg2+, MtTOP1-840t also displayed higher cleavage activity for MT3 
than reaction without Mg2+.  Mutant protein MtTOP1-786t did not show difference 
of cleavage activity with or without Mg2+.  However, the cleavage product of 
MtTOP1-704t was decreased in the presence of Mg2+ likely because DNA 
religation is favored in this reaction.  In the reactions with Mg2+ and 1 M NaCl 
added following DNA cleavage, DNA religation takes place followed by 
dissociation of the enzyme from the religated substrate.  MtTOP1-704t with D5 
subdomain exhibits cleavage activity without Mg2+, but religation activity with 
Mg2+ for short oligo.   It is hypothesized that although the CTD subdomains D6-
D8 have high binding affinity for short oligo, NaCl and Mg2+ dissociate the short 
oligos from topoisomerase CTD and allow short oligos to bind to active site for 
cleavage.  
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Figure 1.17 Cleavage of short oligonucleotide MT3 in the presence of Mg (II).  (A) 
Cleavage assay of wild-type and mutant M. tuberculosis topoisomerase I with 5 mM 
Mg2+ and 1M NaCl.  (B) Cleavage assay of wild-type and mutant M. tuberculosis 
topoisomerase I with 2mM Mg2+. 
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Religaton assay of mycobacterial topoisomerase I with oligonucleotide 
STS32 
The effect of C-terminal subdomains of mycobacterial topoisomerase I on 
religation activity of the longer oligonucleotide substrate STS32 was also 
investigated. Wild-type and mutant mycobacterial topoisomerase I all have 
religation activity to convert the STS32 cleavage product back to the substrate 
when Mg2+ is added to the cleavage reaction.  Wild-type MtTOP1 and MtTOP1-
910t showed less efficient religation activity than MtTOP1-840t, MtTOP1-786t 
and MtTOP1-704t (Figure 1.18, Table 1.5).  Wild-type MsTOP1 and its mutant 
proteins showed similar results as MtTOP1 and its mutant proteins.  Because the 
active site is in the NTD of mycobacterial topoisomerase I, the mutants with 
deletion of the CTD in mycobacterial topoisomerase I can retain religation 
activity.  The DNA binding function of CTD may influence the DNA interaction at 
the active site in NTD or the enzyme conformational change required for bringing 
the ends of the cleaved DNA back together, so MtTOP1, MsTOP1, MtTOP1-910t 
and MsTOP1-909t showed less efficient religation activity.  Relaxation of 
negatively supercoiled DNA requires passage of the complementary DNA strand 
through the break of the strand cleaved at the active site.   The strand passage 
has to take place prior to religation of the DNA break at the active site.   We 
hypothesize that C-terminal subdomain D8 and C-terminal tail are involved in 
binding and passage of a strand of the unwound duplex DNA during relaxation of 
negatively supercoiled DNA by mycobacterial topoisomerase I. 
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Figure 1.18 Comparison of religation activity of wild-type and mutant 
mycobacterial topoisomerase I with oligonucleotide STS32 substrate. 
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A 
 WT MsTOP1 MsTOP1-909t MsTOP1-839t MsTOP1-785t MsTOP1-701t 
Mg2+(mM) 0 5 10 0 5 10 0 5 10 0 5 10 0 5 10 
Cleavage 
product 
level  
0.07 0.03 0.03 0.10 0.05 0.03 0.11 0.01 0.01 0.12 - - 0.17 - - 
 
B 
 WT MtTOP1 MtTOP1-910t MtTOP1-841t MtTOP1-786t MtTOP1-704t 
Mg2+(mM) 0 5 10 0 5 10 0 5 10 0 5 10 0 5 10 
Cleavage 
product level  
0.07 0.02 0.01 0.2 0.03 0.02 0.35 - - 0.35 - - 0.37 - - 
Table 1.5 Product analysis of religation activity of wild-type and mutant mycobacterial topoisomerase I with 
oligonucleotide STS32 substrate.  (A), Product analysis of Wild-type and mutant MsTOP1.  (B), Product analysis of 
wild-type and mutant MtTOP1. The cleavage product was calculated by Cleavage product/total oligo substrate.
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Catenation assay and decatenation assay 
There are two types of IA family topoisomerases, topoisomerase I and 
topoisomerase III in most species of bacteria that have been studied.  Single 
molecule studies have shown that E. coli topoisomerase III (EcTOP III) is much 
more efficient than EcTOP I in DNA catenation/decatenation, while EcTOP I can 
remove negative supercoils much more rapidly (Terekhova et al., 2013, 2014).  
Since M. tuberculosis and other mycobacteria only have one type of IA 
topoisomerase enzyme, MtTOP1 is likely to be required for the resolution of 
ssDNA recombination and replication intermediates.  The catenation activity of 
MsTOP1 has been demonstrated previously with M13 ssDNA since MtTOP1-
704t was found to have robust DNA cleavage–religation capabilities, the 
truncated enzyme was assayed for catenation of single-stranded M13mp18 DNA 
circles to determine if it can catalyze passage of a ssDNA through the break 
created by enzyme cleavage on another ssDNA circle.  The results (Figure 1.19) 
showed that MtTOP1-704t has comparable catenation activity to that of full-
length MtTOP1 and MsTOP1.  The catenated DNA network in kDNA is stable at 
45°C without topoisomerase treatment (Figure 1.20).  Human topoisomerase II 
can decatenate kDNA to generate the monomeric DNA.  This monomeric DNA 
includes nicked open circular DNA and closed circular relaxed DNA. Wild-type 
MtTOP1 has the ability to decatenate kDNA into nicked, open circular DNA, but 
is not able to release decatenated closed circular relaxed DNA because cutting 
of a double-strand of DNA is required.  These results indicated that 
mycobacterial topoisomerase I should be able to resolve topological 
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intermediates in replication and recombination that need passing a single-strand 
of DNA across another single-stranded DNA.  Deletion protein MtTOP1-704t has 
comparable decatenation activity when compared to that of full-length MtTOP1. 
The CTD is not required for this activity. 
 
 
 
Figure 1.19 Catenation of single-stranded M13mp18DNA by MsTOP1, MtTOP1 and 
MtTOP1-704t.  Single-stranded M13mp18 DNA was incubated with the indicated 
amount of MtTOP1 or MtTOP1-704t before proteinase K treatment. C: circular ssDNA; L: 
linear ssDNA; CC: catenated circular ssDNA.  		
 
 
Figure 1.20 Decatenation of kDNA network by MtTOP1 and MtTOP1 704t.  Lane 1, 
negative control, no enzyme; Lane 2, positive control, human topoisomerase IIα. 
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DISCUSSION 
Mutant enzyme MtTOP1-704t maintains cleavage, religation, catenation 
and decatenation activities.  One reason is that the active site tyrosine of 
mycobacterial topoisomerase I is in the NTD.  Deletion of C-terminal subdomain 
D6, D7, D8 and the C-terminal tail does not affect those activities at active site 
and events at the catalytic regions in the NTD.  Escherichia coli AS17 with topAts 
mutation cannot be complemented by MtTOP1-704t or MtTOP1-786t strains at 
42°C  (Figure 1.3) because MtTOP1-704t and MtTOP1-786t lacked the relaxation 
activity required during the cellular process of E. coli AS17.  Partial relaxation 
activities of MtTOP1-840t, MtTOP1-910t, MsTOP1-839t and MsTOP1-909t 
enable growth of E. coli AS17 complemented strains at 42°C.  Proteins with 
NTD+D5+D6+D7 domains that were expressed from a high copy number 
plasmid are sufficient to solve the genomic topological barriers and support the 
growth of E. coli AS17. 
In the DNA binding assay with long oligo STS32 and short oligo MT3, wild-
type MsTOP1 and MtTOP1 displayed higher binding activity than mutant enzyme 
MsTOP1-701t and MtTOP1-704t.  These results demonstrate that CTD for 
mycobacterial topoisomerase I contribute significantly to ssDNA binding.  The 
CTD DNA binding site of mycobacterial topoisomerase I can bind ssDNA with 
higher affinity than the NTD.  The results from the cleavage activity assay of MT3 
with short 14-nucleotide-substrate with and without Mg2+ indicated that before the 
active site is occupied, ssDNA binds to CTD first.  This could explain why for 
wild-type topoisomerase I cleavage of long oligonucleotides STS32 and MT2 
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produces less cleavage products form from 2 pmol and 1 pmol MsTOP1 and 
MtTOP1 than 0.5 pmol of enzyme. Since CTD of mycobacterial topoisomerase I 
has high affinity for ssDNA, higher amount of enzyme binds more ssDNA in its 
CTD.  The increased enzyme: DNA ratio reduces the DNA binding at NTD for 
cleavage by the wild-type mycobacterial topoisomerase I.  Therefore less 
cleavage product was produced when wild-type mycobacterial topoisomerase I is 
in excess. MtTOP1-704t and MsTOP1-701t exhibit higher cleavage activity than 
wild-type mycobacterial topoisomerase I with MT2 (Figure 1.12, Figure 1.13), 
because they do not have the CTD subdomains to compete with the NTD active 
site for DNA binding. It can be postulated that high CTD binding affinity prevents 
the interaction between N-terminal domain of wild-type topoisomerase I with 
DNA, unless both strands of unwound duplex DNA are available in negatively 
supercoiled DNA. 
In the religation activity assays, NaCl serves to dissociate oligos from DNA 
topoisomerases following religation.  A previous study showed that Mg2+ is not 
required for DNA cleavage by wild-type MsTOP1, but Mg2+ is needed for 
religation (Bhat et al., 2009).  In our cleavage assay of mycobacterial 
topoisomerase I with MT3 substrate wild-type MtTOP1 and each mutant enzyme 
responded differently to the presence of Mg2+.  It indicates that Mg2+ may interact 
with the four C-terminal subdomains to affect DNA binding there.  The change in 
CTD-DNA interaction may affect the DNA cleavage-religation at the NTD active 
site in turn.  This may be a direction for future study to understand the role of the 
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mycobacterial topoisomerase I CTD in the conformational change of the enzyme-
DNA complex that accompanies the relaxation of supercoiled DNA. 
In the cleavage assay of MsTOP1-909t with MT3, the cleavage activity of 
MsTOP1-909t did not show the clear response to different amounts of enzyme 
being added. Besides, in the cleavage activity assay of MsTOP1-909t and 
MtTOP1-910t with STS32 substrate, 1 pmol and 2 pmol reactions of these two 
enzymes did not show less cleavage product than 0.5 pmol reactions.  This 
suggests that the C-terminal positively charged tail has a role for ssDNA binding 
in mycobacterial topoisomerase I.  MsTOP1-909t had decreased relaxation 
activity without the C-terminal tail.  The sequence of wild-type MsTOP1’s C-
terminal tail is “RGPVKKKAPAKKAAKKAPAKKAAAKKA”.  It contains 5 lysine 
repeats.  A recent study indicated that the C-terminal lysine repeats found in 
bacterial DNA topoisomerase I stabilize the enzyme-DNA complex (Strzalka et 
al., 2017).  Without the C-terminal positively charged tail to stabilize the enzyme-
DNA complex, the CTD may lose some of the DNA binding affinity. 
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CHAPTER 2: TYPE IA TOPOISOMERASE MECHANISM-ACTIVE SITE 
STRUCTURE AND INTERACTIONS 
ABSTRACT 
Type IA topoisomerases are present in all organisms for multiple vital 
cellular processes that include maintaining optimal DNA supercoiling density, and 
resolution of recombination or replication intermediate.  Their conserved catalytic 
domains form an active site that can cleave and rejoin a single DNA strand.   
Mg2+ is required for catalysis but not for DNA cleavage.  We have obtained new 
structures of Mycobacterium tuberculosis topoisomerase I (MtTOP1).  Crystal 
structure of MtTOP1-704t (amino acids A2-T704) was obtained. Structures with 
ssDNA substrate bound to the active site with and without Mg2+ ion present were 
also investigated.  Significant enzyme conformational changes upon DNA binding 
place the catalytic tyrosine in a pre-transition position for cleavage of a specific 
phosphodiester linkage to form a covalent intermediate.  Meanwhile, the 
enzyme/DNA complex with Mg2+ bound at the active site may present the post-
transition state for religation in the enzyme’s multiple-state DNA relaxation 
activity.  The first observation a divalent metal ion coordinated with the TOPRIM 
residues in the active site of a type IA topoisomerase allows assignment of likely 
catalytic role for the individual divalent ion and draws a comparison to proposed 
mechanism for type IIA topoisomerases.  The critical function of a strictly 
conserved glutamic acid in acid-base catalysis of the DNA cleavage step was 
clearly demonstrated by site-directed mutagenesis.  The functions assigned to 
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the Mg2+ ion can account for the requirement of metal ions for DNA rejoining but 
not DNA cleavage by type IA topoisomerases.  This work provides new functional 
insights into the more stringent requirement for DNA rejoining versus cleavage by 
type IA topoisomerase and further establishes the potential for select interference 
of DNA rejoining by this validated TB drug target.  
 
INTRODUCTION 
Mycobacterium tuberculosis is the chief causative agent of tuberculosis, 
the leading cause of morbidity and mortality globally with an estimated 10.4 
million cases and 1.8 million deaths annually as reported by WHO this year. M. 
tuberculosis topoisomerase I (MtTOP1) is a validated target for much needed 
new antibiotics that can be used against the MDR-TB cases that are difficult to 
treat (Ahmed et al., 2014; Nagaraja et al., 2017; Ravishankar et al., 2015).  
Topoisomerases control the topological state of the genome, thus affecting vital 
cellular processes including replication, transcription, recombination and repair 
(Chen et al., 2013; Wang, 2002).  Type I topoisomerases catalyze DNA 
topological transformations by breaking and rejoining a single-strand of DNA at a 
time, and are divided into type IA and type IB subfamilies based on distinctively 
different protein sequences and catalytic mechanisms (Baker et al., 2008; 
Corbett and Berger, 2004; Vos et al., 2011).  MtTOP1 and topoisomerase I 
present in all bacterial pathogens are type IA topoisomerases that are needed for 
resolving topological barriers that require the passage of DNA through the break 
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created on single-stranded DNA (ssDNA)(Forterre and Gadelle, 2009).  This can 
be exploited for bactericidal action with topoisomerase poison inhibitors that can 
stabilize the break by inhibiting DNA rejoining (Tse-Dinh, 2015).  The bacterial 
type IIA topoisomerases have been targeted extensively for discovery of 
antibiotics that include the widely used fluoroquinolones (Aldred et al., 2014; 
Tomasic and Masic, 2014).  The efforts to discover bacterial topoisomerase I 
inhibitors would be aided greatly by the knowledge of how DNA religation 
following the formation of the covalent intermediate can be inhibited.  
 Type IA topoisomerases share certain functional and structural elements of 
similarities with type IIA topoisomerases (Berger et al., 1998), even though these 
two classes of topoisomerases appear to have evolved independently as 
essential topoisomerase activities in living organisms (Forterre and Gadelle, 
2009).  Both type IA and type IIA topoisomerases form a 5’-phosphoryl tyrosine 
linkage with cleaved DNA in a covalent intermediate (Tse et al., 1980), and 
divalent metal ions are absolutely required for the change in topology catalyzed 
by these topoisomerases.  However, there is a significant difference in the 
biochemical mechanism of these two classes of topoisomerases.  Type IA 
topoisomerases can cleave DNA in the absence of divalent metal ions to form a 
covalent intermediate (Depew et al., 1978), while DNA cleavage by type IIA 
topoisomerases requires the addition of divalent metal ions (Sissi and Palumbo, 
2009).  The requirement of metal ions for DNA religation, but not for DNA 
cleavage by bacterial topoisomerase I may present an opportunity for selective 
inhibition of DNA religation by small molecule inhibitors.  None of the previously 
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determined structures of type IA topoisomerases have divalent metal ions and 
DNA both present at the active site.  The role of metal ions in the catalytic 
mechanism of bacterial topoisomerase I needs to be clarified further by structural 
information.  
In a recent study, the structure of full-length EcTOP I in complex with 
single-stranded DNA was observed (Tan et al., 2015) (PDB ID: 4RUL).  The C-
terminal region of EcTOP I comprises three 4-Cys zinc ribbon motifs and two zinc 
ribbon-like subdomains, and a modular ssDNA-binding mode was reported.  This 
suggests that the C-terminal region of MtTOP1 may also contain multiple 
subdomains with repeated and conserved sequence motifs even though the 
sequences of EcTOP I and MtTOP1 C-terminal regions are very different with 
essentially no homologies.  We analyzed the structural aspects of the C-terminal 
region of mycobacterial topoisomerase I.  The structure organization and 
functional characterizations of subdomains in mycobacterial topoisomerase I 
CTD are described in Chapter 1.  In collaboration with Dr. Kemin Tan at Argonne 
National Laboratory, we first determined the crystal structure of MtTOP1-704t 
with the NTDs (D1–D4) and the CTD D5 (amino acids A2–T704).  Collaboration 
with Dr. Tan also produced additional new structures of M. tuberculosis 
topoisomerase I.  For the first time, divalent metal ion can be observed to 
coordinate DNA, water molecules and the acidic functional groups in the active 
site of a type IA topoisomerase.  We observed metal ion interactions with the 
aspartates in the DxD motif (D111 and D113), proposed previously based on 
genetic and biochemical data.  The invariant glutamic acid (E24) in the TOPRIM 
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domain is in a position for key roles in the catalysis of DNA cleavage-religation.  
The requirement of the carboxyl group on E24 for acid-base catalysis of DNA 
cleavage in the absence of divalent metal ions is further clarified by the study of 
the E24A and E24Q mutants.  Based on the new structural results, we compare 
the active site of topoisomerase IA, IIA, and III; and draw their possible 
similarities and differences in their catalytic mechanisms, particularly between 
topoisomerase IA.  
 
MATERIALS AND METHODS 
Cloning, expression and purification 
The cloning, expression and purification methods of MtTOP1-704t have 
been described in Chapter 1. QuickChange site-directed mutagenesis protocol 
and Phusion Hot Start II High-Fidelity DNA Polymerase (Thermo Scientific) were 
used to construct mutant clones (30 cycles of 95°C for 30 sec, 70°C for 30 sec, 
72°C for 4.5 min).  Plasmids 2O-T MtTOP1 and 2O-T MsTOP1 were used as 
templates. The primers for the PCR amplification are listed in table 2.1.   After 
PCR reaction, the PCR products were purified by electrophoresis in 1% agarose 
gel with TAE buffer.  The template plasmids were digested by treating with Dpn1 
restriction enzyme (New England Biolabs).  NEB turbo competent cells (New 
England Biolabs) were used for the transformation of mutant plasmids.  The 
transformants were plated on the LB + 100 µg/ml carbenicillin + 2% glucose 
plates. Plasmids were purified by GeneJET Plasmid Miniprep Kit (Thermo 
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Scientific).  Nucleotide sequencing (Eurofins genomics) was used to verify the 
complete coding region of plasmids. 
After verifying the sequence of mutant plasmids, mutant clones of 
MsTOP1 were overexpressed in E. coli BL21 star (DE3) strain (Invitrogen).  
Mutant clones of MtTOP1 were overexpressed in E. coli T7 Express crystal strain 
(New England Biolabs).  Cells were grown at 37°C overnight.  Overnight cell 
cultures were diluted 1:100 and incubated in LB medium with 100 µg/ml 
carbenicillin at 30°C to exponential phase (OD600=0.4).  BL21 star (DE3) cell 
culture was induced by 1 mM IPTG. T7 express crystal cell culture was induced 
by 0.4 mM IPTG.  Induced cell culture was grown at 22°C overnight.  Cell 
cultures were centrifuged at 4500 rpm at 4°C for 30 min.  Cell pellets were 
suspended in lysis buffer (50 mM sodium phosphate, 0.3 M NaCl, 10 mM 
imidazole, and 1 mg/ml lysozyme, pH 8.0).  The resuspended cell lysate were left 
on ice for 1 hr.  Four cycles of freeze-thawing were used to lyse cells.  The cell 
lysate was centrifuge at 32000 rpm at 4°C for 2 hr.   Mutant proteins, MtTOP1-
E24A, MtTOP1-E24Q, MsTOP1-E21A and MsTOP1-E21Q, were purified by Ni-
Sepharose 6 Fast Flow chromatography from soluble cell lysate. The protein 
fractions were dialyzed against storage buffer (0.1 M potassium phosphate, 0.2 
mM EDTA pH 8.0, 50% glycerol). 
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Primer name Primer sequence (5’-3’) 
MtTOP1-E24A forward CTTGGTGGGCGACGCGACGATGACCAG 
MtTOP1-E24A reverse CTGGTCATCGTCGCGTCGCCCACCAAG 
MtTOP1-E24Q forward CTTGGTGGGCGACTGGACGATGACCAGTC 
MtTOP1-E24Q reverse GACTGGTCATCGTCCAGTCGCCCACCAAG 
MsTOP1-E21A forward CCTTCGTCGGCGACGCGACAATCACGAGT 
MsTOP1-E21A reverse ACTCGTGATTGTCGCGTCGCCGACGAAGG 
MsTOP1-E21Q forward CTTCGTCGGCGACTGGACAATCACGAGTCG 
MsTOP1-E21Q reverse CGACTCGTGATTGTCCAGTCGCCGACGAAG 
Table 2.1 Primers used for site-directed mutagenesis. 
	
Cleavage assay  
The oligonucleotide substrate STS32 and MTS2-13 were labeled with γ-
32P-ATP at the 5’ end by T4 polynucleotide kinase (New England Biolabs) 
(Table 2.2). The labeling reactions were carried on 37°C for 30 min and 
terminated by heating at 75°C for 15 min.  32P-labeled oligonucleotide substrates 
were purified after the labeling reaction using a Sephadex G-50 (STS32) or 
Sephadex G-25 spin column (MTS2-13).  Purified substrates were eluted in 10 
mM Tris-HCl, pH 8.0.  Serially diluted wild-type and mutant mycobacterial 
topoisomerase I were incubated with 0.5 pmol STS32 or MTS2-13 in 5 µl of 10 
mM Tris–HCl (pH 8.0) at 37°C for 30 min.  To terminate the reactions, the equal 
volume of cleavage stop buffer (79% formamide, 200 mM NaOH, 0.1mM EDTA, 
0.04% bromophenol) was added to the reactions followed by heating at 95°C for 
5 min.  The STS32 cleavage product was separated from the substrate by 
electrophoresis in 15% sequencing gel.  The MTS2-13 cleavage product was 
separated from the substrate by electrophoresis in 20% sequencing gel.  The 
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TBE buffer was used as running buffer.  Gels were analyzed by Phosphor-
lmager. 
 
Oligos name Oligos sequence (5’-3’) 
STS32 5′-CAGTGAGCGAGCTTCCGCêTTGACATCCCAATA-3′ 
MTS2-11 5’-TTCCGCêTTGAC-3’ 
MTS2-13 5’-TTCCGCêTTGACTT-3’ 
MTS2-19 5’-CAGTGAGCGAGCTTCCGCT-3’ 
MTS2-18 5’-CAGTGAGCGAGCTTCCGC-3’ 
MT7 5’-TTCCGCT-3’ 
MT6 5’-TTCCGC-3’ 
Table 2.2 Oligonucleotides used for mycobacterial activity assay.  STS32, MTS11, 
MTS2-13 were used as cleavage reaction substrates.  MTS2-19, MTS2-18, MT7 ad MT6 
were used as standards in electrophoresis analysis of the cleavage products. 	
Electrophoretic mobility shift assay (EMSA) 
The oligonucleotide substrate STS32 was labeled with γ-32P-ATP at the 
5’ end (Table 2.2).  The electrophoretic mobility shift assay was carried on 10 µl 
of 20 mM Tris-HCl (pH 8.0), 100 µg/ml BSA, 18% glycerol, 0.5 mM EDTA. 1-4 
pmol of wild-type MtTOP1, MtTOP1-E24A and MtTOP1-E24Q were incubated 
with 5 pmol STS32 at 37°C for 5 min.  The reactions were placed on ice about 5 
min. The non-covalent protein-DNA complex and free substrate were separated 
with 8% polyacrylamide gel. 0.5×TBE buffer was used as running buffer. The 
gels were vacuum dried at 80°C for 2 hr. The dried gel was analyzed by 
Phosphor-lmager. 
 
	 86	
Identification of cleavage site 
The oligonucleotide substrate STS32, MTS2-11, MTS2-13, MTS2-19, 
MTS2-18, MT7, and MT6 were labeled with γ-32P-ATP at the 5’ end (Table 2.2).  
32P-labeled oligonucleotide substrates MTS2-19 and MTS2-18 were purified after 
the labeling reaction using Sephadex G-25 columns.  32P-labeled oligonucleotide 
substrates MT7 and MT6 were purified after the labeling reaction using 
Sephadex G-15 columns (GE Healthcare). Purified substrates were eluted in 10 
mM Tris-HCl, pH 8.0.   0.5 pmol STS32, MTS2-11 and MTS2-13 were incubated 
with wild-type MtTOP1, wild-type MsTOP1, MtTOP1-704t and MsTOP1-701t in 
10 mM Tris–HCl (pH 8.0) at 37°C for 15min.  Oligonucleotide MTS2-13 (0.5 
pmol) was incubated with wild-type MtTOP1 in 10 mM Tris–HCl (pH 8.0) and 
0.25 mM MgCl2 at 37°C for 15 min.  The equal volume of cleavage stop buffer 
was added to terminate reactions. The reactions were heated at 95 °C for 5 min.  
MTS2-19, MTS2-18, MT7, and MT6 were used as standards in gel 
electrophoresis to identify the cleavage site of mycobacterial topoisomerase I on 
these oligonucleotide substrates. The cleavage product and standards were 
electrophoresed in a sequencing gel (15% for substrate STS32, 20% gel for 
MTS2-13 or other oligonucleotide substrates) 
Religation assay 
The oligonucleotide substrate MT3 and MTS2-13 were labeled with γ-32P-
ATP at the 5’ end. Wild-type and mutant proteins (1 pmol) were incubated with 
0.5 pmol oligonucleotide substrate in 5 µl 10 mM Tris-HCl (pH 8.0) at 37°C for 15 
	 87	
min.  We added 0.25 mM or 2.5 mM MgCl2 into the cleavage reaction 
respectively for 5 min further incubation at 37 °C.  The reactions were terminated 
with equal volume of loading buffer  (79% formamide, 0.2 M NaOH, 0.04% 
bromophenol blue) and heated at 95°C for 5 min.  The reaction products were 
analyzed by electrophoresis in 15% sequencing gel.  The TBE buffer was used 
as running buffer.  Gels were analyzed by Phosphor-lmager. 
 
Relaxation assay 
Wild-type and mutant mycobacterial topoisomerase I were serially diluted. 
Diluted proteins were incubated with 250 ng negatively supercoiled plasmid 
pBAD/thio (purified by CsCl density gradient centrifugation) in 20 µL of 10 mM 
Tris–HCl (pH 8.0), 150 mM NaCl, 0.1 mg/ml gelatin, and 5 mM MgCl2 at 37°C for 
30 min.  The relaxation reactions were terminated by addition of 4 µL of stop 
buffer (50 mM EDTA, 50% glycerol and 0.5% (v/v) bromophenol blue).  The DNA 
was then electrophoresed in a 1% agarose gel with TAE buffer (40 mM Tris-
acetate, pH 8.0, 2 mM EDTA).  The gels were stained with 1 µg/mL ethidium 
bromide for 1 hr and photographed over UV light.  
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RESULTS 
Cleavage and religation activity assay of MtTOP1-704t with oligonucleotide 
MTS2-13 
The MtTOP1-704t is used here for determination of the enzyme structure 
by X-ray crystallography in collaboration with Dr. Kemin Tan at Argonne National 
Laboratory.  The biochemical catalytic activity of MtTOP1-704t has been 
described in Chapter 1.  MtTOP1-704t lacks relaxation activity with negatively 
supercoiled DNA.  It retains catenation and decatenation activity with single-
stranded circular or catenated kDNA.  It can cleave and religate long 
oligonucleotides STS32, MT2, and short oligonucleotide MT3.  In Figure 2.1, it 
exhibits the cleavage activity with oligonucleotide MTS2-13.  Wild-type MtTOP1 
shows little cleavage activity with MTS2-13 because the oligonucleotide is 
binding to the CTD under these reaction conditions.  With the addition of Mg2+, 
MtTOP1-704t religated cleaved MTS2-13 (Figure 2.2).  These results indicates 
that Mg2+ is required for catalysis but not for DNA cleavage. 
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Figure 2.1 Assay of MTS2-13 cleavage by wild-type MtTOP1 and MtTOP1-704t.  (A) 
Assay of 32P-labeled MTS2-13 cleavage by wild-type MtTOP1 and MtTOP1-704t.  (B) 
Analysis of cleavage product from MT2-13 with wild-type MtTOP1 and MtTOP1-704t. 
The average and standard deviation from two separate experiments is shown. 
 
 
 
 
 
	 90	
 
 
 
 
 
 
 
 
                                  
 
Figure 2.2 Religaton assay of MtTOP1-704t with MTS2-13.  Wild-type MtTOP1-704t 
reacted with 0.5 pmol MTS2-13 oligosubstrate 37 °C for 15 min.  MgCl2 were added into 
the  cleavage reaction respectively for 5 min further incubation at 37 °C.   
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The crystal structure of MtTOP1-704t 
MtTOP1 contains four GxxGPY sequence motifs in its C-terminal region. 
Based on the locations of the four GxxGPY repeats, we divided the region into 
four repeat domains (Figure 1.1, Figure 1.2).  MtTOP1-704t is one of the 
constructs that have been made based on the CTD prediction mentioned above. 
It spans from amino acid A2 to amino acid T704 and includes the N-terminal 
subdomains, D1-D4 along with C-terminal subdomain D5.  The crystal structure 
of MtTOP1-704t is showed in Figure 2.3 (PDB ID: 5D5H).  The 15 N-terminal 
residues (A2-S16) are not visible in the structure.  The NTD (G17-A638) of 
MtTOP1-704t has a similar toroid assembly as EcTOP I (G2-N590) NTD (Tan et 
al., 2016).  The D1 subdomain contains the region from G17 to G50, and region 
from P87 to D157.  It is observed to have five β-turns and a short β-hairpin. The 
hinge subdomain D2 comprises two sequentially separated regions: from F213 to 
R302 (β1-β2-α1-β3) and from D434 to R516 (β4-β5-α2-β6).  D3 is an all-α-helical 
subdomain (from P303 to A433), including the catalytic residue Y342.  The two 
regions of D4 subdomain link to D1 and D5 subdomains.  
The D5 subdomain is the first C-terminal subdomain of MtTOP1.  It 
extends from residue R638 to P705.  It contains a four-stranded antiparallel β-
sheet with a C-terminal helix packed against the β-sheet on one side (Figure 
2.3).  Hydrophobic interaction dominates the interaction between the β-sheet and 
the helix.  The helix apparently plays an important role in stabilizing the β-sheet 
and the small subdomain.  The conserved tyrosine Y665, the third residue of the 
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β3 strand, is predicted to be a key residue in the interaction of D5 with DNA by 
forming π-stackings with the bases.  
 
 
 
 
Figure 2.3 The crystal structure of MtTOP1-704t.  (A) A ribbon diagram of the 
structure of MtTOP1-704t. The N-terminal D1, D2, D3 and D4 subdomains, are colored 
cyan, pink, blue and yellow.  The C-terminal D5 subdomain is colored green.  (B) 
Structure of MtTOP1 first C-terminal subdomain D5. Conserved Y665 are highlighted. 
The program Pymol was used for the preparation. 
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Co-crystals of MtTOP1-704t with short ssDNA substrates 
Co-crystallization trials of MtbTOPI-704t were set up with MTS 
(Mycobacterial Topoisomerase Substrate) oligonucleotides of various lengths 
with sequences derived from a 32 nucleotide long substrate (STS32) previously 
identified as having a strong topoisomerase site (STS)(Bhat et al., 2009).  
Multiple crystal forms were harvested, and their X-ray diffraction data were 
collected.  The highest resolution data set (2.42 Å) was obtained from a co-
crystal with a short, 11-mer oligonucleotide (MTS2-11, 5’-TTCCGCTTGAC-3’).  
This crystal structure (MtTOP1-704t/MTS2-11) (PDB: 6CQI) represents a 
topoisomerase I/ssDNA complex in the absence of metal ions at the active site 
(Figure 2.4). 
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Figure 2.4 Structure of MtTOP1-704t/ssDNA complex.  The ribbon diagram of one 
structure of MtTOP1-704t in complex with MTS2-11.  The five individual subdomains, 
D1-D5 are colored in cyan, pink, blue, yellow and green, respectively.  The phosphate 
backbone of oligonucleotide is in orange with its polarity labeled.  The catalytic residue, 
Y342 is drawn for highlighting its position. The program Pymol was used for the 
preparation. 					
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Conformation of ssDNA substrate and its kink 
 The ssDNA MTS2-11 is intact in the structure (Figure 2.4).  Its sugar-
phosphate backbone is mostly buried along the bottom of the DNA-binding 
groove from D4 to the edge of the D1-D3 interface in a 5’ to 3’ direction (Figure 
2.4, Figure 2.5A).   The bases of the seven nucleotides from positions -4 to +3 
resemble the stacking conformation of one B-DNA strand as described earlier for 
DNA bound to E. coli topoisomerase III (EcTOP III) (Changela et al., 2001) and 
topoisomerase I (EcTOP I)(Perry and Mondragón, 2003).  This conformation is 
interrupted between the -4 and -5 positions with a backbone kink and insertion of 
a tyrosine side chain from the enzyme (Y176) between the two bases (Figure 
2.5B).  The kink contributes to the recognition of cytosine at the -4 position 
relative to the scissile phosphate for all preferred bacterial topoisomerase I 
cleavage sites (Annamalai et al., 2009; Narula and Tse-Dinh, 2012; Zhang et al., 
2011).  Aside from the interactions with the -4 cytosine base involving R168, 
R172 and Y176, there are additional enzyme-ssDNA interactions, including a 
series of arginine-phosphate salt bridges mediated by R194, R344 and R547 
(Figure 2.5B and Figure 2.6).   
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Figure 2.5 Conformation of ssDNA substrate and its interaction to MtTOP1-704t.   
(A) The ssDNA bound to MtTOP1-704t resembles a B-DNA conformation, which is 
interrupted between -4 and -5 positions.  The 2FoFc electron density map is drawn in 
grey mesh and contoured at 1σ level and within 2.1 Å of the ssDNA, which is drawn in 
stick format.  (B) Part of interaction between ssDNA and MtTOP1-704t.  Several arginine 
residues involved in the interaction to either phosphate backbone (R194 and R547) or 
bases (R167, R168 and R172) are presented.  One anchoring site of ssDNA to MtTOP1-
704t is located at the phosphate group between -3 and -4 positions.  The phosphate 
group is positioned below the N-terminus of the α3 helix of D4, which has an equivalent 
charge about +0.5 unit.  In the apo structures of MtTOP1-704t, a phosphate group or a 
sulfide group from crystallization buffer is commonly found at this position.  The tyrosine 
Y176 inserts between the bases at -4 and -5 positions, helping create a kink on the base 
packing of ssDNA.  The residue Y176 forms π-π stacking with bases at both -4 and -5 
positions.  Both Fig.2A and 2B were prepared based on the MtTOP1-704t/MTS2-11 
structure (PDB code: 6CQI).  
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Active-site conformation in the absence of Mg2+-binding 
The conformational change upon ssDNA binding not only helps create the 
gate for the passing of the T-strand, it also brings catalytic residues together to 
form an active site.  The active site configuration of MtTOP1-704t/ MTS2-11, in 
the absence of Mg2+ ion, is similar to that of the covalent complex of EcTOP I 
and EcTOP III/ssDNA complexes, but with new features (Figure 2.6A).  The 
catalytic tyrosine Y342 makes two hydrogen bonds from top to the scissile 
phosphate, including one to its bridging 5’-oxygen atom and one to a non-
bridging O atom (Figure 2.6 A).  The distance between the hydroxyl groups of 
Y342 to the phosphorous of the scissile phosphate is 2.96 Å.  The scissile 
phosphate is being positioned on one side by R344 through an arginine-
phosphate salt bridge, and on the other side by E24 through a hydrogen bond 
from its bridging 3’-oxygen atom (Figure 2.6A).  E24 also forms a hydrogen bond 
with the amide group of D111, bridging the catalytic residue to the scissile 
phosphate.   
The MtTOP1-704t/MTS2-11 structure does not have any positively 
charged lysine side chain interacting with the DNA at the active site while in the 
EcTOP III/ssDNA complex, lysine K8 interacts with the putative scissile 
phosphate.  The positively charged K8 was believed to help stabilize the negative 
charge on non-bridging oxygens of the pentavalent transition state (Changela et 
al., 2001).   However, in MtTOP1 as well as in EcTOP I, this lysine residue is not 
conserved, being replaced by a serine in the bacterial topoisomerase I 
sequences (Strahs et al., 2006).   A nearby lysine K28 in MtTOP1 (equivalent to 
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K13 in EcTOP I) is more than 6.5 Å away from the scissile phosphate by 
measuring the distances between K28 Nζ atom to the oxygen atoms of the 
phosphate (Figure 2.6 A).  The absence of EcTOP III K8 equivalent in MtTOP1 
and EcTOP I active site structures implies some difference in the catalytic 
mechanisms of bacterial topoisomerase I and topoisomerase III, as suggested 
earlier (Terekhova et al., 2012; Zhang et al., 2011).  The side chain of D111 is 
quite mobile without well-defined electron density in electron density maps.  
D111 can potentially make a hydrogen bond with an invariant H389 on the long 
loop between α3 and α4 helices of D3.   H389 also forms a displaced and tilted π 
H (hydrogen) interaction with Y342 in this MtTOP1-704t/MTS2-11 complex.   It is 
noted that the α3_α4 loop of D3 is very flexible, allowing the position and 
conformation of the strictly conserved histidine to be highly variable from 
structure to structure.  Similar observations were made for the covalent EcTOP I 
complex as well as in the open and the mutant forms of EcTOP III, in which the 
histidine forms a nearly parallel displaced π-π stacking with catalytic tyrosine.  
However, in the closed and the intermediate forms of EcTOP III, there is no 
interaction between these two residues.   This flexible α3_ α4 loop of D3 and the 
conserved histidine could play a potential role in charge relay in the DNA 
cleavage and religation steps (Perry and Mondragon, 2002).   The direct π-π 
interaction with the catalytic tyrosine may also allow this invariant histidine to 
assist in stabilization of the transition state for DNA cleavage in the absence of 
Mg2+. 
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Structure of active site with bound Mg2+ ion 
Magnesium plays an essential role in DNA religation by type IA 
topoisomerase (Tse-Dinh, 1986).  However, divalent ion has never been 
observed in any co-crystal structures of topoisomerase IA-DNA complex.   After 
the extensive screening of MtTOP1-704t/ssDNA crystals grown under different 
conditions, one crystal structure of MtTOP1-704t in complex with a 13-mer 
oligonucleotide, MTS2-13 reveals a mode of metal binding at the enzyme active 
site (Figure 2.6B).   Compared to the structure of MtTOP1-704t/ssDNA in the 
absence of metal ion (Figure 2.6A), the extra electron densities in an 
approximately globular shape between the scissile phosphate and the carboxyl 
groups of E24 and D111 strongly indicate a metal binding site, Mg2+(1) in Figure 
2.6B.  One water molecule, W (1), was assigned to completes the coordination of 
the metal ion, forming a trigonal bipyramid genometr, in which E24, OP1 and W1 
are equatorial ligands while D111 and O3 are axial.  It is worthwhile to mention 
that the position of the sidechain of D111 is not well-defined in electron density 
maps.  After applying only Mg-O bond distance restrain (2.10 ± 0.10 Å) to the 
metal binding site in the subsequent structural refinements, the trigional pyramid 
geometry is quite stable and the model fits the electron densities well.   
Interestingly, the water W1 forms a hydrogen bond with another TOPRIM acidic 
residue D113 (Figure 2.6B) proposed previously (Aravind et al., 1998; Bhat et al., 
2009) to interact with divalent Mg2+. After obtaining this MtTOP1-704t/MTS2-
13/Mg complex structure, a second structure with a metal ion bound at the same 
site was determined after extensive screening of crystals formed in different 
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conditions, particularly in conditions with added MgCl2 in the crystallization 
buffers. The addition of Mg2+ in the crystallization buffer did not simply increase 
Mg2+ binding, at least under the buffer condition used. 
 
 
Figure 2.6 Active sites in the absence and in the presence of Mg2+.  (A) The active 
site interaction pattern between MtTOP1-704t and ssDNA (MTS2-11) in the absence of 
Mg2+.  The key residues from MtTOP1-704t and ssDNA are drawn in stick format.  All 
hydrogen bonds and salt bridges are drawn in magenta dash lines.  The residue K28, as 
discussed in text, is too far away from scissile phosphate.  The 2FoFc electron density 
map is drawn in grey mesh and contoured at 1s level and within 2.1 Å of the ssDNA, the 
residues of E24, D111, D113 and Y342.  (B) The active site interaction pattern between 
MtTOP1-704t and ssDNA (MTS2-13) in the presence of Mg2+.  The MtTOP1-704t 
complex shown in this figure is slightly rotated along the horizontal axis in respect to that 
shown in Figure 2.6A for better view of Mg2 binding site.  Besides hydrogen bonds and 
salt bridges, all Mg–O bonds are also drawn in magenta dash lines.   The 2FoFc 
electron density map is drawn in grey mesh and contoured at 1σ level and within 2.1 Å 
of the ssDNA, the residues of E24, D111, D113 and Y342, and the meal ion and water 
molecules. The insert figure displays simulated annealing omit maps of metal-binding 
site, 2Fo-Fc map in grey at contour level of 1σ, and Fo-Fc map in pink at contour level of 
5σ.  The simulated annealing refinement with a starting temperature of 5000K was 
performed with Mg2+ and W1 being omitted. 				
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Mapping of exact cleavage site on single-stranded oligonucleotide 
substrates 
In each of the crystal structures of the enzyme-DNA complex reported 
here, there is a DNA phosphate positioned at a distance from Tyr342 expected 
for the scissile phosphate.   We confirmed that this is indeed the scissile 
phosphate for the cleavage of oligonucleotides MTS2-11 and MTS2-13 by PAGE 
analysis of the cleavage product, using shorter 5’-end labeled oligonucleotides 
for comparison (Figure 2.7 A, B).   We also confirmed that both MtTOP1 and M. 
smegmatis topoisomerase I (MsTOP1) cleave at the same site in oligonucleotide 
STS32, a 32-base long ssDNA oligonucleotide from which the sequence of these 
shorter oligonucleotide substrates has been derived (Figure 2.7C).  This 
cleavage position is shifted by one nucleotide towards the 5’-end from the 
position expected from the previous report (Bhat et al., 2009).   This could be due 
to differences in enzyme preparation, cleavage reaction conditions, and cleavage 
site mapping protocols (Sikder and Nagaraja, 2000).  
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Figure 2.7 Identification of cleavage site with MTS2-11, MTS2-13 and STS32 
oligonucleotide substrate.  (A) Identification of cleavage site with MTS2-11.  Lane 1: 
No enzyme.  Lane 2: 1 pmol MtTOP1 cleavage product with oligo.  Lane 3: 1 pmol 
MtTOP1 cleavage product with 0.5 mM Mg2+ added.  Lane4: 1 pmol MtTOP1 cleavage 
product with 0.5 mM Mg2+ and 1 M NaCl added.  Lane5: Oligo standard MT7.  Lene6: 
Oligo standard MT6.  Lane 7: 1 pmol MtTOP1-704t cleavage product.  Lane 8: 1 pmol 
MtTOP1-704t cleavage product with 0.5mM Mg2+ added.  Lane9: 1 pmol MtTOP1-704t 
cleavage product with 0.5 mM Mg2+  and 1 M NaCl added.  (B) Identification of cleavage 
site with MTS2-13.  Lane 4 and Lane 11: Oligo standard MT6.  Lane 5 and Lane 12: 
Oligo standard MT7.  Lane 9 and lane 10 is cleavage product with 0.25mM Mg2+ added.  
(C) Identification of cleavage site with STS32.  1 pmol MtTOP1-704t, MtTOP1 and 
MsTOP1 were used in Lane 2,3 and 6. Lane 4: Oligo standard MTS2-18. Lane 5, Oligo 
standard MTS2-19. 
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Requirement of the strictly conserved Glu24 carboxyl side chain for DNA 
cleavage 
 The ~100 amino acid long TOPRIM domains found in type IA and type IIA 
topoisomerases have two strictly conserved sequence motifs of acidic residues 
that play important roles in the catalysis of these topoisomerases, as well as 
other nucleotidyl transfer enzymes that require Mg2+ for their activities (Aravind et 
al., 1998).  The first motif is centered around a conserved glutamate that 
corresponds to residue E24 in MtTOP1 and E9 in EcTOP I respectively.  The 
second motif is at the two conserved aspartates present as DxD (D111 and D113 
in MtTOP1).  Site-directed mutagenesis of EcTOP I has shown that alanine 
substitution at E9 abolishes DNA relaxation activity, and the E9A mutant could 
not cleave DNA (1998; Zhu et al., 1998).  A role for this conserved glutamate in 
acid-base catalysis of DNA cleavage and rejoining has been proposed, with the 
glutamate side chain providing the proton for the 3’-OH leaving group during 
DNA cleavage, and enhancing the nucleophilic properties of the 3’-OH during 
DNA religation.  E24 of MtTOP1 is well positioned for these roles as seen in the 
structure with MTS2-11 in the absence of divalent ions as the likely structure 
prior to the DNA cleavage step, and in the structure with MTS2-13 in the 
presence of Mg2+ as the probable structure post DNA religation.  The critical 
functions of the strictly conserved glutamate E24 may be assisted by charge 
relay involving D111 and H389, with water molecules in the hydrogen-bonding 
network at the active site being potential participants in the acid-base catalysis.  
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D111 and H365 in EcTOP I are well positioned for the proposed charge relay 
(Perry and Mondragon, 2002).  The sequence of charge relay during DNA 
cleavage would involve donation of a proton from the invariant histidine to the 
nearby aspartate, which then relays the charge to the strictly conserved 
glutamate so that it can be protonated at physiological pH to act as a general 
acid for neutralizing the negative charge on the 3’-hydroxyl leaving group.  The 
bell-shaped pH dependence of EcTOP I catalysis is modified by H365 mutations 
(Perry and Mondragon, 2002) is consistent with the role of this conserved 
histidine in optimal catalysis at physiological pH (Perry and Mondragon, 2002).  A 
nearby water molecule can potentially replace the role of the histidine for 
donating a proton if the histidine is mutated to another residue.  However, the 
role of EcTOP I glutamate E9 as a general acid during DNA cleavage is 
inconsistent with the reported retention of DNA cleavage activity for the EcTOP I 
E9Q mutant (Chen and Wang, 1998).  In order to clarify the catalytic role of this 
critical conserved glutamic acid residue, we mutated E24 of MtTOP1 to alanine 
or glutamine.  Both the MtTOP1-E24A and MtTOP1-E24Q mutants had null 
relaxation activity as well as no observable DNA cleavage activity (Figure 2.8 A, 
B).  Similar results were obtained for the MsTOP1 E21A and E21Q mutants 
(Figure 2.9).  Gel shift assay of non-covalent binding to the oligonucleotide 
substrate showed that the activities of the MtTOP1-E24A and MtTOP1-E24Q 
mutant proteins are unaffected prior to the DNA cleavage step (Figure 2.8C).  
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Figure 2.8 Substitutions in MtTOP1 E24 prevent relaxation of supercoiled DNA and 
ssDNA cleavage by the enzyme without affecting non-covalent DNA binding.  (A) 
Relaxation assay:  Agarose gel electrophoresis of products from incubation of 
supercoiled pBAD/Thio plasmid DNA with wild-type MtTOP1 and E24A, E24Q mutant 
enzymes at 37°C for 30 min. (B) ssDNA cleavage assay: STS32 oligonucleotide labeled 
with 32P at the 5’-end was incubated with enzymes at 37°C for 15 min.  The substrate 
and product were separated by electrophoresis in a 15% sequencing gel.  (C) ssDNA 
binding assay of wild-type and mutant MtTOP1: Electrophoretic mobility shift assay for 
formation of non-covalent complex between labeled STS32 oligonucleotide and  
enzyme.  The graph shows average and   means from results of three experiments. 
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Figure 2.9 Substitutions in MsTOP1-E21 prevent ssDNA cleavage by the enzyme.  
(A) Relaxation assay. Serial diluted MsTOP1, MsTOP1-E21A and MsTOP1-E21Q were 
incubated with 250 ng pBAD/Thio plasmid DNA 37°C for 30min. (B) ssDNA cleavage 
assay.  ssDNA cleavage assay: STS32 oligonucleotide labeled with 32P at the 5’-end 
was incubated with enzymes at 37°C for 15 min.  The substrate and product were 
separated by electrophoresis in a 15% sequencing gel. 
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DISSCUSSION 
In the model of DNA cleavage proposed for type IIA topoisomerases 
(Schmidt et al., 2010), a divalent metal ion and a conserved arginine interact with 
the scissile phosphate to stabilize the transition state while a second metal ion 
interacts with the -1 phosphate to position the scissile phosphate in the active 
site for cleavage by the tyrosine nucleophile.  We propose that for bacterial 
topoisomerase I, the strictly conserved arginine (R344 in MtTOP1) is mainly 
responsible for an electrostatic interaction with the scissile phosphate to allow 
DNA cleavage to take place in the absence of metals (Figure 2.10A).   A water 
molecule may act as a general base (B:) to extract a proton from the active site 
tyrosine Y342, facilitating nucleophilic attack.  The positively charged side chain 
of R344 interacts with both the tyrosine oxygen and the transition state to 
stabilize the negative charges.  E24 acts as general acid to protonate the 3’-O 
leaving group.  D111 and H389 are in place for charge relay to assist E24.  This 
proposed scheme is supported by the previously observed requirement of Mg2+ 
for DNA cleavage by EcTOP I mutants with the conserved arginine (R321) 
altered to an aromatic residue that can interact with the active site tyrosine 
through hydrophobic interaction, but cannot provide any electrostatic interaction 
(Narula et al., 2011; Narula and Tse-Dinh, 2012).  The stacking interaction 
between the invariant histidine (H389 in MtTOP1) and the catalytic tyrosine may 
also help to stabilize the DNA cleavage transition state in the absence of Mg2+. 
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A                                                            B 
 
Figure 2.10 Proposed schemes for DNA cleavage and religation. (A) Proposed 
schemes for DNA cleavage in the absence of divalent ions. (B) Proposed schemes for 
DNA reliagtion in the presence of divalent ion. 
 
The preferred DNA cleavage sites of MtTOP1 have a cytosine base at the 
-4 position upstream of the scissile phosphate (Annamalai et al., 2009).  This 
cleavage site preference holds true for all bacterial topoisomerase I, but not for 
topoisomerase III.  We propose that the interactions of R168, R172, Y176 (Figure 
2.5) with the cytosine base in the -4 position serve the role of the second metal 
ion proposed for type IIA topoisomerase for positioning the DNA substrate 
(Schmidt et al., 2010), ensuring that the tyrosine hydroxyl is at the required 
distance from the scissile phosphate in the active site for DNA cleavage to take 
place.  Analysis of the site-directed alanine substitution mutations of the EcTOP I 
residues required for interaction with the cytosine in the -4 position showed that 
the mutants have significantly decreased DNA cleavage activity, and that the 
preference of the cytosine in the -4 position can be altered to an adenine base 
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instead (Narula and Tse-Dinh, 2012).  Topoisomerase III enzymes do not have 
the requirement of a cytosine base in the -4 position for preferred cleavage sites 
to utilize this mechanism for aligning the active site tyrosine with the scissile 
phosphate.  A lysine conserved in topoisomerase III enzymes (K8 in EcTOP III) 
has been proposed to replace the role of a metal ion required by type IIA 
topoisomerase in the active site (Schmidt et al., 2010).  A lysine is conserved in 
bacterial topoisomerase I in a nearby, but non-equivalent position (K13 in EcTOP 
I, K28 in MtTOP1).  Site-directed mutagenesis of EcTOP I K13 showed that this 
lysine is required for DNA cleavage (Strahs et al., 2006), but its positively 
charged side chain is not in the vicinity of the scissile phosphate in all the EcTOP 
I crystal structures available to date.  We also find that K28 is not near the DNA 
phosphates in the active site of MtTOP1-704t bound to DNA in the absence or 
presence of metal ions (Figure 2.6).  We cannot dismiss the possibility that K28 
of MtTOP1 and its equivalent lysine in other bacterial topoisomerase I can move 
into the active site to interact with the transition state in a reaction intermediate 
that has not been captured by crystallography.  It is also possible that the role of 
K13 in EcTOP I and K28 in MtTOP1 in catalysis is different from K8 in EcTOP III, 
as their positions are not equivalent.  The lysine conserved in this specific 
position of bacterial topoisomerase I may be required for the assembly of the 
active site.  It may also have a polarizing effect on the nearby acidic residues, as 
previously proposed (Strahs et al., 2006). 
Because type IA topoisomerases break and rejoin a single-strand of DNA that 
is not base-paired to its complementary strand, Watson-Crick base pairing is not 
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available to help align the 3’-OH and 5’-phosohoryl group linked to the tyrosine in 
the covalent intermediate for rejoining.  Therefore, we propose that there is a 
stringent requirement for the presence of the metal ion to be present for these 
DNA ends to be joined into a phosphodiester linkage in the DNA religation step. 
Metal ion is required to position the 3’-hydroxyl group as the nucleophile at a 
required distance from the phosphotyrosine linkage.  The metal ion could be 
involved in positioning the 5’-phosphoryl tyrosine, and in the stabilization of the 
transition state for DNA rejoining (Figure 2.10B).  Such roles for the divalent ion 
would differ from the classic two-metal ion mechanism, with both metal ions 
interacting with the transition state, and one metal assisting in the activation of 
the nucleophile while the other metal stabilizes the leaving group (Strahs et al., 
2006).  There are also significant differences from the mechanism proposed for 
type IIA topoisomerase (Schmidt et al., 2010), with both metal ions assisting the 
acid-base catalysis by interacting with the transition state and the second metal 
ion interacting with an adjacent phosphate to anchor the substrate DNA.  We 
cannot disregard any movement of the metal ion in type IA and type IIA 
topoisomerases during catalysis to facilitate nucleophile formation and stabilize 
both transition state and leaving group as expected for the canonical two-metal 
ion mechanism (Schmidt et al., 2010; Strahs et al., 2006).  Nevertheless, 
bacterial topoisomerase I may have evolved to have a metal ion involved in 
forming and stabilizing the transition state for DNA rejoining because of the 
single-stranded state of the DNA strand during cleavage-religation, and the 
utilization of a cytosine binding pocket for positioning the DNA substrate for 
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cleavage instead of using a metal ion for such purpose.  The 3’-OH nucleophile is 
activated by Mg2+ in DNA rejoining (Figure 2.10B).  The positive charge of the 
conserved arginine (R344 in MtTOP1) interacting with the active site tyrosine-
leaving group is essential for DNA rejoining.  DNA cleavage intermediate 
accumulates in vivo when this arginine in EcTOP I (R321) is mutated to a 
hydrophobic amino acid (Narula et al., 2011).  The presence of Mg2+ cannot 
compensate for the absence of the arginine positive charge for DNA rejoining.  
Therefore even though a metal may be in a position to stabilize the negative 
charge of the tyrosine hydroxyl leaving group as expected for the canonical two-
metal ion mechanism, the positive charge of this arginine is still required for 
interacting with the tyrosine hydroxyl negative charge during DNA rejoining. 
Certain mutants of EcTOP I and MsTOP1 with specific substitutions at the 
conserved arginine and aspartates in the active site have been demonstrated to 
be dominant lethal (Bhat et al., 2009; Tse-Dinh, 2009).  These mutant enzymes 
can still cleave DNA while DNA rejoining in the presence of Mg2+ became less 
efficient, resulting in accumulation of covalent intermediates and bacterial cell 
death (Cheng et al., 2009; Narula et al., 2011; Tse-Dinh, 2009).  MtTOP1 is 
essential for the viability of the TB pathogen, and can be exploited as a novel 
target for discovery of new therapies (Godbole et al., 2015; Nagaraja et al., 2017; 
Ravishankar et al., 2015; Sandhaus et al., 2016) in the treatment of MDR-TB.  
Genetic manipulation to deplete MtTOP1 and inhibition of MtTOP1 activity by 
small molecules have been shown to inhibit growth (Godbole et al., 2015; 
Ravishankar et al., 2015). Significant bactericidal activity may require only a 
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small number of the trapped covalent topoisomerase-DNA intermediates (Aedo 
and Tse-Dinh, 2012) through the action of topoisomerase poison inhibitors 
(Pommier, 2013; Pommier et al., 2010).  Small molecules that can selectively 
perturb the MtTOP1 active site interactions in the presence of Mg2+ observed in 
the structure of enzyme/DNA/Mg complex reported here may be candidates for 
topoisomerase poison inhibitors against MtTOP1.   
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